

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number
WO 2004/039841 A2

(51) International Patent Classification⁷: **C07K 14/715**

(74) Common Representative: **BOREAN PHARMA A/S**;
Gustav Wieds Vej 10, DK-8000 Aarhus C (DK).

(21) International Application Number:
PCT/DK2003/000735

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 29 October 2003 (29.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2002 01634 29 October 2002 (29.10.2002) DK
60/421,807 29 October 2002 (29.10.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*):
BOREAN PHARMA A/S [DK/DK]; Gustav Wieds Vej 10, DK-8000 Aarhus C (DK). **OTTOW, Helle, Krogh** [DK/DK]; Langballevej 74, DK-8320 Mårslet (DK).

Published:

— *without international search report and to be republished upon receipt of that report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HOLTET, Thor, Las** [DK/DK]; Strandvejen 4, DK-8410 Rønne (DK). **ANDERSEN, Mikkel, Holmen** [DK/DK]; Skt. Pauls Gade 68 1. Sal, DK-8000 Århus C (DK).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **TRIMERIC BINDING PROTEINS FOR TRIMERIC CYTOKINES**

(57) Abstract: The present invention pertains to the provision of trimeric binding units which bind to trimeric cytokines. In particular there is provided a trimeric polypeptide comprising a trimerising domain and three monomers with binding members capable of binding a trimeric cytokine. Preferably, the trimeric binding units bind in a manner such that upon binding, all receptor binding sites of the trimeric cytokine are substantially blocked, and hence the potential biological activity of the trimeric cytokine is suppressed. In one aspect the invention relates to trimeric binders capable of binding to trimeric cytokines of the Tumor necrosis factor ligand superfamily, such as TNF, TRAIL, RANKL, TWEAK, APRIL and BAFF.

BEST AVAILABLE COPY

WO 2004/039841 A2

Trimeric binding proteins for Trimeric Cytokines

Field of the invention

The present invention pertains to the provision of trimeric binding proteins which bind to trimeric cytokines. In particular there is provided trimeric binders that bind in a manner such that upon binding, all receptor binding sites of the trimeric cytokine are substantially blocked, and hence the potential biological activity of the trimeric cytokine is suppressed. In one aspect the invention relates to trimeric binders capable of binding to cytokines of the Tumour necrosis factor ligand superfamily, including tumour necrosis factor (TNF).

Background of the invention and prior art

Cytokines are small secreted polypeptides from higher eukaryotes which are responsible for intercellular signal transduction and which affect the growth, division and functions of other cells. They are potent, pleiotropic polypeptides that, e.g. via corresponding receptors, act as local or systemic intercellular regulatory factors, and therefore play crucial roles in many biologic processes, such as immunity, inflammation, and hematopoiesis (formation and development of blood cells in the bone marrow). Cytokines are produced by diverse cell types including fibroblasts, endothelial cells, macrophages/monocytes, and lymphocytes. To date, a large number of cytokines have been identified, including interferons, tumour necrosis factors, interleukins and lymphokines. They differ from classical hormones in that they are produced by a number of tissues or cell types rather than by specialized glands.

The modulation of cytokine-receptor interactions can be a useful mechanism for therapeutic intervention in various diseases and pathologies. Soluble binding proteins, which can interact with cytokines, can potentially sequester the cytokine away from the receptor, thereby reducing or preventing the activation of that particular receptor pathway.

Certain cytokines occur as multi-subunit complexes containing multiple copies of the same subunit. Macrophage migration inhibitory factor (MIF) and proteins within the tumour necrosis factor ligand super family (TNFLSF), such as Tumour necrosis factor (TNF; TNFLSF member 2) and lymphotoxin alpha (LT-alpha; TNFLSF member 1), occur as homotrimers formed by three identical subunits. Many of these trimeric cytokines are known to be involved in signal transduction and to act as regulatory factors, and to be involved in many different types of diseases and medical indications.

The trimeric cytokines of the TNF ligand super family are known to control and orchestrate the immune and inflammatory responses at several levels. It is also known that TNF ligand super family members are associated with several disease conditions, such as acute or chronic inflammatory conditions. Presently, the TNF ligand super family has at least 17 recognised ligands, including LTA (lymphotoxin alpha; TNFLSF member 1), TNF (tumor necrosis factor; TNFLSF member 2), LTB (lymphotoxin beta; TNFLSF member 3), OX-40L (TNFLS member 4); CD40L (TNFLS member 5); FasL (TNFLS member 6); CD27L (TNFLS member 7); CD30L (TNFLS member 8); 4-1BB-L (TNFLS member 9); TRAIL (TNFLS member 10); RANKL (TNFLS member 11); TWEAK (TNFLS member 12); APRIL (TNFLS member 13); BAFF (TNFLS member 13B); LIGHT (TNFLS member 14); VEGI (TNFLS member 15); and GITRL (TNFLS member 18).

Evidence exist that the signalling unit of the trimeric cytokines of the TNF ligand super family and their corresponding receptors, is in the form of three receptors and three ligands assembled as a hexameric complex in which a single cytokine trimer binds to three receptor molecules (Bodmer et al. 2002, *TRENDS in Biochemical Sciences* 27(1), pp. 19-26). Before becoming part of this hexameric complex, the receptors exist in monomeric form. This general mechanism is illustrated in Figure 1.

TNF (TNFLSF member 2) is one of the principal mediators of the immune and inflammatory response, and it is e.g. known to have an important role in the pathogenesis of rheumatoid arthritis, which is a common autoimmune inflammatory disease that affects approximately 0.5-1% of the human population. Additionally, TNF is also known to be involved in the pathogenesis of a wide range of disease states,

including endotoxin shock, cerebral malaria and graft-versus-host reaction. TNF is produced by a number of cell types, mainly by activated macrophages. The soluble form of TNF consists of three identical 17 kD protein subunits, whereas the membrane bound form consist of three identical 26 kD subunits. TNF is also previously known as "TNF-alpha" and "cachectin".

TWEAK (TNFLSF member 12) was recently found to be a direct and strong inducer of angiogenesis (formation and growth of blood vessels) as it was observed that picomolar concentrations of TWEAK promote proliferation of normal endothelial cells and that TWEAK induces angiogenesis in an *in vivo* rat cornea model (Lynch et al., 1999, The Journal of Biological Chemistry, 274(13) pp. 8455-8459). In particular angiogenesis is essential for the growth and persistence of solid tumours and their metastases, and it is also known to be involved in other pathological conditions such as diabetic retinopathy, psoriasis, contact dermatitis and restenosis.

In US20020037852A1 the trimeric cytokine BAFF (TNFLS member 13B) was described to be expressed by T cells and dendritic cells for the purpose of B-cell co-stimulation and consequently may play an important role in the control of B cell function. It is suggested therein that BAFF and its receptor may have anti-cancer and immunoregulatory applications as well as uses for the treatment of immunosuppressive disorders such as HIV.

APRIL (TNFLS member 13) is a trimeric cytokine that binds to the receptor TNFRSF13B and to TNFRSF17. It has recently been shown that the addition of recombinant APRIL to various tumor cells stimulates their proliferation and hence APRIL may be implicated in the regulation of tumor cell growth (Hahne M., et al, 1998; J. Exp. Med. 188:1185-1190). It has also been suggested that APRIL may be involved in monocyte/macrophage-mediated immunological processes.

Furthermore, cytokines within the TNF super family have also been described to be involved in hereditary diseases such as hyper IgM syndrome, type I autoimmune lymphoproliferative syndrome, TNF-R1-associated periodic fever syndrome, hypohidrotic ectodermal dysplasia and familial expansile osteolysis.

Several attempts have been made in order to find and develop suitable antagonists and binders for trimeric cytokines which are capable of binding to specific trimeric cytokines and thereby preventing the trimeric cytokines from binding to e.g. cell membrane bound receptors and hence suppressing the activation of that particular receptor pathway.

One example is antagonists against the trimeric cytokine TNF (TNFLSF member 2). Presently, two types of TNF antagonists are commercially available, namely Infliximab (Remicade) and Eternarcept (Enbrel) which have both received marketing authorization in the United States and Europe for treatment of rheumatoid arthritis. The two products have also been shown to be effective for the treatment of psoriasis and Crohn's disease. Infliximab is a chimeric antibody with murine variable regions and human IgG1 and γ constant regions, which neutralizes the biological activity of TNF by binding to the soluble and transmembrane forms of TNF and inhibits the binding of TNF with its receptors. The structure of Infliximab is similar to that of naturally occurring antibodies. Eternarcept is a fusion protein made up of the extracellular domain of the p75 TNF receptor and the hinge and Fc domains of human IgG1.

Another example of an antagonist for a trimeric cytokine is given in WO 00/42073 where a monoclonal antibody against the trimeric cytokine TWEAK (TNFLS member 12) is disclosed. It is mentioned that the antibody can block the development of Graft-Versus-Host Disease.

However, a common technical problem that is encountered with the presently known binders and inhibitor products for trimeric cytokines, is that upon formation of a 1:1 complex of the trimeric cytokine and the binder or inhibitor product, not all three receptor binding sites of the trimeric cytokines are effectively blocked, as at least one or two of the three receptor binding sites are left open. The open cytokine receptor binding site(s) may associate with a corresponding cell surface cytokine receptor and thereby, due to high local concentration of the receptors on the cell surface, initiate the further recruitment of cytokine receptors and mediate receptor signalling.

The problem is clearly illustrated by the TNF binder Eternaccept, which is a bivalent molecule that forms a 1:1 complex with the TNF trimer. When Eternaccept binds to TNF, only two out of three possible receptor binding sites are occupied by the Eternaccept molecule, and the third receptor binding site is left open. This implies that the open TNF receptor binding site may associate with a cell surface TNF receptor and thereby, due to high local concentration of the receptors on the cell surface, initiate the further recruitment of TNF receptors and by that signal transduction. This problem is illustrated in Figure 2.

The same problem is seen with the TNF binder Infliximab. Each Infliximab molecule is only capable of binding one receptor binding site (subunit) of a given TNF molecule, hence leaving out two open receptor binding sites. These open receptor binding sites may subsequently associate with corresponding free receptors, resulting in further recruitment of TNF receptors and receptor signalling.

It has now been found by the present inventors, that the above technical problems may be overcome by the provision of a fusion protein (protomer) which is constructed as a fusion of a binding unit (binder) for trimeric cytokines to a trimerising domain. The fusion protein of the present invention is, as a trimeric protein, capable of forming a 1:1 complex with a trimeric cytokine and preferably at the same time effectively binding all three receptor binding sites of the trimeric cytokines, whereby no receptor binding sites are left open, and is therefore able to inhibit docking of the cytokine to the cell surface. Thus, there is now provided a fusion protein which has the advantage of being capable of more effectively inhibiting and neutralising the biological activity of trimeric cytokines as compared to presently known trimeric cytokine antagonists. A further advantage of the fusion protein according to the invention is that when applied as a medicament, less amount of the fusion protein is required in order to obtain a therapeutic effect, as compared to the presently known binders for trimeric cytokines.

Summary of the invention

Accordingly, the invention relates in a first aspect to a trimeric polypeptide comprising three monomers, each of said monomers comprising a specific binding member

capable of binding a trimeric cytokine, and each of said monomers comprising a trimerising domain.

In a further aspect there is provided a pharmaceutical composition comprising the trimeric polypeptide according to the invention.

In a still further aspect, the invention pertains to a method of treating a subject having a pathology mediated by a trimeric cytokine such as tumour necrosis factor, by administering an effective amount of the trimeric polypeptide according to the invention to the subject,

Finally, there is provided a method for the preparation of the trimeric polypeptide according to invention, and an assay method for detecting a trimeric polypeptide cytokine in a sample.

Detailed disclosure of the invention

In one aspect, the present invention provides trimeric binders which are capable of binding to trimeric cytokines, preferably in a manner such that upon binding, all receptor binding sites of the trimeric cytokine are substantially blocked and/or neutralised, and hence the potential biological activity of the trimeric cytokine is suppressed or neutralised. Accordingly, there is provided a trimeric polypeptide comprising three monomers, wherein each of the monomers comprise a specific binding member which is capable of binding a trimeric cytokine, and wherein each of the monomers comprise a trimerising domain.

In the present context, the term "trimeric cytokine" refers to small proteins and fragments thereof, which are produced and secreted by a cell, and which elicit a specific response in a cell which has a receptor for that cytokine, e.g. by affecting the growth, division and/or function of the cell. The term "trimeric" is used herein to describe that the cytokines according to the invention occur as multi-subunit complexes containing three subunits, preferably three identical subunits (homotrimer).

Typical examples of such trimeric cytokines include Macrophage migration inhibitory factor (MIF) and cytokines within the tumour necrosis factor ligand super family (TNFLSF). Presently, as mentioned above, the TNF ligand super family has at least 17 recognised ligands which all share a conserved trimeric C-terminal domain known as the "TNF homology domain" (THD), which is responsible for receptor binding. The sequence identity of this trimeric domain is approximately 20-30% between TNF family members. The THD is a 150 amino acid long sequence containing a conserved framework of aromatic and hydrophobic residues which is illustrated in Figure 2 in Bodmer et al. 2002, *TRENDS in Biochemical Sciences* 27(1), pp. 19-26. Accordingly, in the present context a "member of the Tumor necrosis factor ligand superfamily" is intended to mean a trimeric protein comprising the TNF homology domain, THD. Presently known trimeric cytokines within the TNF ligand super family are listed below in Table 1, together with synonyms and their corresponding Genbank ID (GenBank, National Center for Biotechnology Information; <http://www.ncbi.nlm.nih.gov/Genbank>). The nomenclature for the TNF ligand superfamily as used herein follows the official TNF superfamily (TNFSF) nomenclature which may be found at <http://www.gene.ucl.ac.uk/nomenclature/genefamily/tnftop.html>.

TABEL 1: TNF ligand superfamily

Ligand symbol	Genbank ID	Synonyms
LTA	X01393	TNFSF1, TNFB, LT
TNF	X02910	TNFSF2, TNF-alpha, DIF
LTB	L11016	TNFSF3, TNFC, p33
TNFSF4	D90224	OX-40L, gp34, TXGP1
TNFSF5	X67878	CD40LG, IMD3, HIGM1, CD40L, hCD40L, TRAP, CD154, gp39
TNFSF6	U11821	FasL, APT1LG1
TNFSF7	L08096	CD70, CD27L, CD27LG
TNFSF8	L09753	CD30LG
TNFSF9	U03398	4-1BB-L
TNFSF10	U37518	TRAIL, Apo-2L, TL2
TNFSF11	AF013171	TRANCE, RANKL, OPGL, ODF
TNFSF12	AF030099	TWEAK, DR3LG, APO3L
TNFSF13	NM_003808	APRIL
TNFSF13B	AF136293	BAFF, THANK, BLYS, TALL-1, TALL1, TNFSF20
TNFSF14	AF036581	LIGHT, LTg, HVEM-L
TNFSF Fn14	-	Fibroblast growth factor-inducible immediate-early response protein 14, FGF-inducible 14, Tweak-receptor, TweakR
TNFSF15	AF039390	TL1, VEGI
TNFSF18	AF125303	AITRL TL6 hGITRL

Accordingly, in one useful embodiment of the invention the trimeric polypeptide according to the invention is capable of binding a trimeric cytokine which is a member of the Tumor necrosis factor ligand superfamily selected from LTA; TNF ;LTB; TNFSF4; TNFSF5; TNFSF6; TNFSF7; TNFSF8; TNFSF9; TNFSF10; TNFSF11; TNFSF12; TNFSF13; TNFSF13B; TNFSF14; TNFRSF Fn14; TNFSF15; and TNFSF18.

The term "specific binding member", as used herein, refers to a member of a pair of molecules which have binding specificity for one another. The members of a specific binding pair may be naturally derived or wholly or partially synthetically produced. One member of the pair of molecules has an area on its surface, or a cavity, which specifically binds to and is therefore complementary to a particular spatial and polar organisation of the other member of the pair of molecules. Thus the members of the pair have the property of binding specifically to each other. Examples of types of specific binding pairs are antigen-antibody, biotin-avidin, hormone-hormone receptor, ligand-ligand receptor, enzyme-substrate. Other examples of specific binding pairs include, carbohydrates and lectins, complementary nucleotide sequences (including probe and capture nucleic acid sequences used in DNA hybridization assays to detect a target nucleic acid sequence), complementary peptide sequences including those formed by recombinant methods, effector and receptor molecules, enzyme cofactors and enzymes, enzyme inhibitors and enzymes, and the like. Furthermore, specific binding pairs can include members that are analogues or fragments of the original specific binding member.

In useful embodiments, the specific binding members capable of binding a trimeric cytokine, provides the trimeric polypeptide according to the invention with a binding affinity (K_d) for the trimeric cytokine that preferably is 1×10^{-8} M or less determined by surface plasmon resonance. In other useful embodiments, the K_d value is less than 1×10^{-9} M, 1×10^{-10} M, 1×10^{-11} M, 1×10^{-12} M, 1×10^{-13} M, 1×10^{-14} M, or even less than 1×10^{-15} M. In further useful embodiments, the K_{off} rate for the trimeric polypeptide according to the invention is less than $1 \times 10^{-3} \text{ s}^{-1}$, such as less than $1 \times 10^{-4} \text{ s}^{-1}$, including less than $1 \times 10^{-5} \text{ s}^{-1}$, and even less than $1 \times 10^{-6} \text{ s}^{-1}$ determined by surface

plasmon resonance. The term "K-off", as used herein, is intended to refer to the off rate constant for dissociation of a specific binding member from the specific binding member/trimeric cytokine complex. The term "surface plasmon resonance", as used herein, refers to an optical phenomenon that allows for the analysis of real-time biospecific interactions by detection of alterations in protein concentrations within a biosensor matrix, for example using the BIAcore system (Pharmacia Biosensor AB, Uppsala, Sweden). For further descriptions, see Example 10.

As mentioned above, it is preferred that the trimeric cytokine binder according to the invention at least partially or fully blocks, inhibits, or neutralises a biological activity of a trimeric cytokine. As used herein, the expression "neutralises" or "neutralisation" means the inhibition of or reduction in a biological activity of a trimeric cytokine as measured *in vivo* or *in vitro*.

In useful embodiments the specific binding member is a polypeptide derived from a member of the Tumor necrosis factor receptor superfamily. Presently, at least 29 receptors within the Tumor necrosis factor superfamily are known, and listed below in Table 2 together with their synonyms and their corresponding Genbank ID (GenBank, National Center for Biotechnology Information; <http://www.ncbi.nlm.nih.gov/Genbank>). The nomenclature for the members of the TNF receptor superfamily as used herein follows the official TNF superfamily (TNFSF) nomenclature which may be found at <http://www.gene.ucl.ac.uk/nomenclature/genefamily/tnftop.html>.

TABEL 2: TNF receptor superfamily

Receptor Symbol	Genbank ID	Synonyms
TNFRSF1A	M75866	p55-R, CD120a, TNF-R-I p55, TNF-R, TNFR1, TNFAR, TNF-R55, p55TNFR, TNFR60
TNFRSF1B	M32315	CD120b, p75, TNF-R, TNF-R-II, TNFR80, TNFR2, TNF-R75, TNFBR, p75TNFR
LTBR	L04270	TNFRSF3, TNFR2-RP, CD18, TNFR-RP, TNFCR, TNF-R-III
TNFRSF4	X75962	OX40, ACT35, TXGP1L
TNFRSF5	X60592	p50, Bp50, CD40
TNFRSF6	M67454	FAS, CD95, APO-1, APT1
TNFRSF6B	AF104419	DcR3, M68, TR6, HGNC:15888, NHL, DKFZP434C013, KIAA1088, bK3184A7.3, C20orf41
TNFRSF7	M63928	Tp55, S152, CD27
TNFRSF8	M83554	Ki-1, D1S166E, CD30
TNFRSF9	L12964	4-1BB, CD137, ILA
TNFRSF10A	U90875	DR4, Apo2, TRAILR-1

Receptor Symbol	Genbank ID	Synonyms
TNFRSF10B	AF012628	DR5, KILLER, TRICK2A, TRAIL-R2, TRICKB
TNFRSF10C	AF012536	DcR1, TRAILR3, LIT, TRID
TNFRSF10D	AF029761	DcR2, TRUNDD, TRAILR4
TNFRSF11A	AF018253	RANK
TNFRSF11B	U94332	OPG, OCIF, TR1
TNFRSF12	U72763	DR3, TRAMP, WSL-1, LARD, WSL-LR,DDR3, TR3, APO-3
TNFRSF12L	-	DR3L
TNFRSF13B	AF023614	TACI
TNFRSF13C	AF373846	BAFFR
TNFRSF14	U70321	HVEM, ATAR, TR2, LIGHTR, HVEA
NGFR	M14764	TNFRSF16, p75NTR
TNFRSF17	Z29574	BCMA, TNFRSF13
TNFRSF18	AF125304	AITR, GITR
TNFRSF19	AB040434	TAJ-alpha, TROY, TAJ, TRADE
TNFRSF19L	AF319553	FLJ14993, RELT
TNFRSF21	AF068868	DR6
TNFRSF22	-	SOBa, Tnfrh2, 2810028K06Rik
TNFRSF23	-	mSOB, Tnfrh1

Thus, in useful embodiments the specific binding member derived from a receptor within the Tumor necrosis factor superfamily is selected from the receptors TNFRSF1A, TNFRSF1B, LTBR, TNFRSF4, TNFRSF5, TNFRSF6, TNFRSF6B, TNFRSF7, TNFRSF8, TNFRSF9, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11B, TNFRSF12, TNFRSF12L, TNFRSF13B, TNFRSF13C, TNFRSF14, NGFR, TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF19L, TNFRSF21, TNFRSF22, and TNFRSF23. However, it is also contemplated that further useful receptors may be identified within this protein family, and hence further functional specific binding members.

In a useful embodiment, the specific binding member is derived from the TNF receptors TNFRSF1A (TNF α receptor) and/or TNFRSF1B (TNF β receptor). Especially the TNFRSF1B receptor and subunits thereof has proven to be effective for specifically binding and neutralising TNF. As an example, the TNF binding protein Eterncept is a fusion protein made up of the extracellular domain of the TNFRSF1B receptor, i.e. a subunit of the TNFRSF1B receptor. Accordingly, in specific embodiments, the trimeric polypeptide according to invention includes a specific binding member which is a subunit or fragment of the TNFRSF1B receptor (TNF β),

such as the TNFRSF1B receptor fragments disclosed in US 5,712,155. Thus, in useful embodiments the specific binding member is a polypeptide comprising an amino acid sequence selected from TNFRSF1B 1-235 (SEQ ID NO:76), TNFRSF1B 1-185 (SEQ ID NO:77), TNFRSF1B 1-163 (SEQ ID NO:78) and TNFRSF1B 1-142 (SEQ ID NO:79).

In further useful embodiments, as disclosed in following examples, the specific binding member may be one or more fragments of the TNFRSF1B receptor (TNFRII) and combinations of such fragments, such as a polypeptide comprising an amino acid sequence encoded by a DNA sequence selected from TNFRSF1B D1D2 (SEQ ID NO:13), TNFRSF1B D1D2, 1/6 (SEQ ID NO:15), TNFRSF1B D1D2 1/4 (SEQ ID NO:17), TNFRII D1D2, 1/3 (SEQ ID NO:19), TNFRSF1B D1D2, 1/2 (SEQ ID NO:21), TNFRSF1B D1D4 (SEQ ID NO:23), TNFRSF1B D2 (SEQ ID NO:25), TNFRSF1B D2, 1/6 (SEQ ID NO:26), TNFRSF1B D2, 1/4 (SEQ ID NO:27), TNFRSF1B D2, 1/3 (SEQ ID NO:28), TNFRSF1B D2, 1/2 (SEQ ID NO:29) and TNFRSF1B D2D4 (SEQ ID NO:30).

In accordance with the invention, the specific binding member capable of binding a trimeric cytokine may also be an antibody or an antibody fragment. In the present context, the term "antibody" is used to describe an immunoglobulin whether natural or partly or wholly synthetically produced. As antibodies can be modified in a number of ways, the term "antibody" should be construed as covering any specific binding member or substance having a binding domain with the required trimeric cytokine specificity. Thus, this term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or wholly or partially synthetic. Chimeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. The term also covers any polypeptide or protein having a binding domain which is, or is homologous to, an antibody binding domain, e.g. antibody mimics. These can be derived from natural sources, or they may be partly or wholly synthetically produced. Examples of antibodies are the immunoglobulin isotypes and their isotypic subclasses; fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd; and

diabodies.

US 6,451,983 B2 describes antibodies for human tumour necrosis factor which are i.a. capable of neutralising the biological activity of TNF. In particular, US 6,451,983 B2 provides antibodies and fragments thereof which are capable of binding to mature human TNF (SEQ ID NO:80) within certain specific topographic regions. Accordingly, in useful embodiments of the present invention, the specific binding member is an antibody or fragment thereof which is capable of binding mature human TNF (SEQ ID NO:80) in at least one region selected from the regions consisting of amino acid residues 1-18, 1-20, 1-26, 1-30, 12-22, 22-31, 22-40, 36-45, 49-97, 49-98, 56-79, 58-65, 69-97, 70-87, 76-90, 96-105, 105-128, 108-128, 110-127, 115-125, 117-128, 132-157, 135-155, 136-153, 138-149, 141-153 and 146-157.

US 6,451,983 B2 further provides specific monoclonal antibodies which may be useful in the present invention. Accordingly, the specific binding member capable of binding human TNF may be an antibody or antibody fragment selected from MAb 1 (ECACC 89080301), MAb 21 (ECACC 90012432), MAb 25 (ECACC 89121401), MAb 32 (ECACC 89080302), MAb 37 (ECACC 89080303), MAb 42 (ECACC 89080304), MAb 47 (ECACC 89121402), MAb 53 (ECACC 90012433) and MAb 54 (ECACC 89083103), wherein ECACC refers to European Collection of Animal Cell Cultures.

Further examples of useful antibodies include the humanised antibody D2E7 as disclosed in US 6,090,382 and the humanised antibody fragment CDP 870 as disclosed in WO/00194585.

In specific embodiments, the specific binding members of the present invention may comprise antibody analogues or artificial antibodies such as e.g. a protein having the scaffold structure of C-type lectin-like domains (CTLD) as disclosed in WO/0248189. As will be apparent from the following Examples, useful human tetranectin based CTLD antibody analogues which are capable of binding TNF may be selected from TN3-2-B (SEQ ID NO:103), TN3-2-C (SEQ ID NO:104) and TN3-2-D (SEQ ID NO:105).

An important aspect of the present invention is that the monomers of the trimeric polypeptide, in addition to the specific binding member, further comprise a trimerising domain. In the present context, the term "trimerising domain" is a peptide, a protein or part of a protein which is capable of interacting with other, similar or identical trimerising domains. The interaction is of the type that produces trimeric proteins or polypeptides. Such an interaction may be caused by covalent bonds between the components of the trimerising domains as well as by hydrogen bond forces, hydrophobic forces, van der Waals forces and salt bridges.

One example of a trimerising domain is disclosed in WO 95/31540, which describes polypeptides comprising a collectin neck region. The amino acid sequence constituting the collectin neck region may be attached to any polypeptide of choice. Trimers can then be made under appropriate conditions with three polypeptides comprising the collectin neck region amino acid sequence.

In a presently preferred embodiment, the trimerising domain is derived from tetranectin, and more specifically comprises the tetranectin trimerising structural element (hereafter termed TTSE) which is described in detail in WO 98/56906. The amino acid sequence of TTSE is shown in SEQ ID NO:81. The trimerising effect of TTSE is caused by a coiled coil structure which interacts with the coiled coil structure of two other TTSEs to form a triple alpha helical coiled coil trimer which is exceptionally stable even at relatively high temperatures. The term TTSE is also intended to embrace variants of a TTSE of a naturally occurring member of the tetranectin family of proteins, variants which have been modified in the amino acid sequence without adversely affecting, to any substantial degree, the capability of the TTSE to form alpha helical coiled coil trimers. Thus, the trimeric polypeptide according to the invention may comprise a TTSE as a trimerising domain, which comprises a sequence having at least 68% amino acid sequence identity with the sequence of SEQ ID NO:81, such as at least 75%, including at least 87%, such as at least 92%. In accordance herewith, the cystein residue No. 50 of the TTSE (SEQ ID NO:81) may advantageously be mutagenised to serine, threonine, methionine or to any other amino acid residue in order to avoid formation of an unwanted inter-chain disulphide bridge, which could lead to unwanted multimerisation.

In a further embodiment, the TTSE trimerising domain (SEQ ID NO:81) may be modified by (i) the incorporation of polyhistidine sequence and/or a cleavage site for the Blood Coagulating Factor X_a, (ii) replacing Cys 50 with Ser, and (iii) by including a C-terminal KGS sequence.

Several examples of different trimeric polypeptides in accordance with the invention are provided in the following in examples, in which the above TTSE trimerising domain has been applied. These includes i.a. the CTLD based TNF binding units TN-2-B (SEQ ID NO:106), TN-2-C (SEQ ID NO:108) and TN-2-D (SEQ ID NO:107), and the trimerised human TNFRII fragment AD1D4-GSS-I10 (SEQ ID NO:109).

In accordance with the invention, the specific binding member may either be linked to the N- or the C-terminal amino acid residue of the trimerising domain. However, it is also envisaged that in certain embodiments it may be advantageous to link a specific binding member to both the N-terminal and the C-terminal of the trimerising domain of the monomer, and thereby providing a trimeric polypeptide comprising six specific binding members capable of binding a trimeric cytokine.

It will be appreciated that a flexible molecular linker optionally may be interposed between, and covalently join, the specific binding member and the trimerising domain. In certain embodiments, the linker is a polypeptide sequence of about 1-20 amino acid residues. The linker may be less than 10 amino acids, most preferably, 5, 4, 3, 2, or 1. It may be in certain cases that 9, 8, 7 or 6 amino acids are suitable. In useful embodiments the linker is essentially non-immunogenic, not prone to proteolytic cleavage and does not comprise amino acid residues which are known to interact with other residues (e.g. cystein residues).

The trimeric polypeptide of the present invention may be expressed in any suitable standard protein expression system by culturing a host transformed with a vector encoding the trimeric polypeptide under such conditions that the trimeric polypeptide is expressed. Preferably, the expression system is a system from which the desired protein may readily be isolated and refolded *in vitro*. As a general matter, prokaryotic

expression systems are preferred since high yields of protein can be obtained and efficient purification and refolding strategies are available. Thus, it is well within the abilities and discretion of the skilled artisan, without undue experimentation, to choose an appropriate or favourite expression system. Similarly, once the primary amino acid sequence for the trimeric polypeptide of the present invention is chosen, one of ordinary skill in the art can easily design appropriate recombinant DNA constructs which will encode the desired proteins, taking into consideration such factors as codon biases in the chosen host, the need for secretion signal sequences in the host, the introduction of proteinase cleavage sites within the signal sequence, and the like. These recombinant DNA constructs may be inserted in-frame into any of a number of expression vectors appropriate to the chosen host. The choice of an appropriate or favourite expression vector is, again, a matter well within the ability and discretion of the skilled practitioner. Preferably, the expression vector will include a strong promoter to drive expression of the recombinant constructs. Finally, the trimeric polypeptide may be isolated using suitable standard procedures well known in the art, and optionally subjected to further processing such as e.g. lyophilization.

The trimeric polypeptide according to the invention may be used for the preparation of a pharmaceutical composition by any suitable method well known in the art. The composition may together with the trimeric polypeptide, comprise one or more acceptable carriers therefore, and optionally other therapeutic ingredients. The carriers must be acceptable in the sense of being compatible with the other ingredients and not deleterious to the recipient thereof. In general, methods for the preparation of pharmaceutical compositions include the step of bringing into association the active ingredient and a carrier.

The therapeutic application of the present invention comprises the treatment of a disease or disorder in an animal, by administering a therapeutically effective amount of the trimeric polypeptide according to the invention to an animal in need thereof. As mentioned above, trimeric cytokines, and in particular trimeric cytokines of the TNF ligand super family, are known to be pleiotropic polypeptides that act as intercellular signal transduction molecules by i.a. controlling and coordinating immune and inflammatory responses. Thus, it will be appreciated that the trimeric polypeptide of the

present invention may be applicable for the treatment of wide range of disorders and diseases mediated by trimeric cytokines, including inflammatory diseases, autoimmune disorders, immune disorders, infections, malignancies, and neurogenerative diseases. In one useful embodiment the disease is a pathology mediated by tumor necrosis factor, such as rheumatoid arthritis, psoriasis and Crohn's disease.

The trimeric polypeptide of the present invention may be directly administered to the animal by any suitable technique, including parenterally, and can be administered locally or systemically. The specific route of administration depends, e.g., on the medical history of the animal. Examples of parenteral administration include subcutaneous, intramuscular, intravenous, intraarterial, and intraperitoneal administration.

The animals potentially treatable by the trimeric fusion protein herein include mammals such as a human.

Finally, the present invention provides an assay method for detecting a trimeric polypeptide cytokine in a sample which comprises (i) contacting the sample with a trimeric polypeptide according to the invention, and (ii) detecting the binding of the trimeric polypeptide to the trimeric cytokine.

The invention will now be described by way of illustration in the following non-limiting examples and figures.

Description of the figures

Figure 1 shows the binding of a trimeric cytokine within the Tumour Necrosis Factor Super Family to a corresponding cell bound monomeric receptor, which initiates the further recruitment of two more cytokine receptors resulting in the formation of a hexameric cytokine-receptor signalling unit.

Figure 2 shows the binding of a bivalent binder to a trimeric cytokine within the Tumour Necrosis Factor Super Family (TNFSF), which forms a 1:1 complex with the

trimeric cytokine. When the bivalent binder binds to the trimeric TNFSF cytokine, only two out of three possible receptor binding sites are occupied by the bivalent binder molecule, and the third receptor binding site is left open. This implies that the open trimeric cytokine receptor binding site may associate with a cell surface trimeric cytokine receptor and thereby, due to high local concentration of the receptors on the cell surface, initiate the further recruitment of trimeric receptors and thereby signal transduction.

Figure 3 shows a binder for trimeric cytokines which is capable of forming a 1:1 complex with a trimeric cytokine and at the same time effectively binding all three receptor binding sites of the trimeric cytokine, whereby no receptor binding sites are left open. The docking of the cytokine to the cell surface is blocked, and hence no signal transduction will occur.

Figure 4 shows inhibition of TNF alpha mediated cytotoxicity in a murine fibroblast cell line L929 assay at two different fixed TNF alpha concentrations (1.0 ng/ml and 0.1 ng/ml) for the trimerised receptor fragment D1D4GSSI10 Trip in 10-fold dilutions.

Examples

EXAMPLE 1

Design and construction of trip E. coli expression plasmids and phagemids for the production of trimeric cytokine binders

Phagemids

The phagemid, psktripB, was constructed by ligation of the Sfi I and Not I restricted DNA fragment sktripB amplified from the expression plasmid pTtripb with the oligonucleotide primers C-sfikpn-TRI (SEQ ID NO:1) and N-sfikpn-TRI (SEQ ID NO:2) into a Sfi I and Not I pre-cut vector, pCANTAB 5E supplied by Amersham Pharmacia Biotech (code no. 27-9401-01) using standard procedures. The nucleotide sequences of the sktripB inserts is given as SEQ ID NO:3.

The phagemid, pskl10tripB, was constructed by ligation of the Sfi I and Not I restricted DNA fragment skl10tripB amplified from the expression plasmid pTtripb with the oligonucleotide primers C-sfikpn-TRI (SEQ ID NO:1) and N-sfikpn-I10TRI (SEQ ID NO:4) into a Sfi I and Not I pre-cut vector, pCANTAB 5E supplied by Amersham Pharmacia Biotech (code no. 27-9401-01) using standard procedures. The nucleotide sequence of the skl10tripB inserts is given as SEQ ID NO: 5.

Expression plasmids

The expression plasmid pT7H6-bktripB, was constructed by ligation of the BamH I and Hind I restricted DNA fragment bktripB, amplified from the expression plasmid pTtripb with the oligonucleotide primers C-bamkpn-TRI (SEQ ID NO:6) and N-bamkpn-TRI (SEQ ID NO: 7), into the BamH I and Hind I restricted expression plasmid pT7H6 using standard procedures. The nucleotide sequence of bktripB is given as SEQ ID NO:8.

The expression plasmid pT7H6-bkl10tripB, was constructed by ligation of the BamH I and Hind I restricted DNA fragment bkl10tripB, amplified from the expression plasmid pTtripb with the oligonucleotide primers C-bamkpn-TRI (SEQ ID NO: 6) and N-bamkpn-I10TRI (SEQ ID NO:9), into the BamH I and Hind I restricted expression plasmid pT7H6 using standard procedures. The nucleotide sequence of bkltripB is given as SEQ ID NO:10.

Example 2

Design and construction of a trimeric TNF binders using TNFRII fragments

Fragments and subunits of the TNF receptor TNFRSF1B (TNFRII) was used for the construction of trimeric TNF binders based on the trimerising domain TripB derived from tetranectin. The design and cloning is outlined in the following:

Cloning of TNFRSF1B fragments into Phagemid vectors

The Phagemid vector pD1D2tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and

7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D2kpn-fo (SEQ ID NO: 12)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2, is given as SEQ ID NO:13.

The Phagemid vector pD1D2,1/6tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D1/6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) D1/6kpn-fo (SEQ ID NO: 14)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2,1/6, is given as SEQ ID NO:15.

The Phagemid vector pD1D2,1/4tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D1/4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D1/4kpn-fo (SEQ ID NO: 16)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2,1/4, is given as SEQ ID NO:17.

The Phagemid vector pD1D2,1/3tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D1/3 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D1/3kpn-fo (SEQ ID NO: 18)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2,1/3, is given as SEQ ID NO:19.

The Phagemid vector pD1D2,1/2tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D1/2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D1/2kpn-fo (SEQ ID NO: 20)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2,1/2, is given as SEQ ID NO:21.

The Phagemid vector pD1D4tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D4kpn-fo (SEQ ID NO: 22)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D4, is given as SEQ ID NO:23.

The Phagemid vector pD1D2I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D2kpn-fo (SEQ ID NO: 12)) into a Sfi I and Kpn I cut vector, pskI10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2, is given as SEQ ID NO:13.

The Phagemid vector pD1D2,1/6I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D1/6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D1/6kpn-fo (SEQ ID NO: 14)) into a Sfi I and Kpn I cut vector, pskI10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2,1/6, is given as SEQ ID NO:15.

The Phagemid vector pD1D2,1/4I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D1/4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D1/4kpn-fo (SEQ ID NO: 16)) into a Sfi I and Kpn I cut vector, pskI10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2,1/4, is given as SEQ ID NO:17.

The Phagemid vector pD1D2,1/3I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D1/3 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1

and 7182-1) (with the oligonucleotide primers D1-rev: (SEQ ID NO: 11) and D1/3kpn-fo (SEQ ID NO: 18)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2,1/4, is given as SEQ ID NO:19.

The Phagemid vector pD1D2,1/2I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D1/2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D1/2kpn-fo (SEQ ID NO: 20)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D2,1/2, is given as SEQ ID NO:21.

The Phagemid vector pD1D4I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1D4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D1-rev (SEQ ID NO: 11) and D4kpn-fo (SEQ ID NO: 22)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D1D4, is given as SEQ ID NO:23.

The Phagemid vector pD2tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D2kpn-fo (SEQ ID NO: 12)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D2, is given as SEQ ID NO:25.

The Phagemid vector pD2,1/6tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1/6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D1/6kpn-fo (SEQ ID NO: 14)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D2,1/6, is given as SEQ ID NO:26.

The Phagemid vector pD2,1/4tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1/4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D1/4kpn-fo (SEQ ID NO: 16)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D2,1/4, is given as SEQ ID NO:27.

The Phagemid vector pD2,1/3tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1/3 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D1/3kpn-fo (SEQ ID NO: 18)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D2,1/3, is given as SEQ ID NO:28.

The Phagemid vector pD21/2tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1/2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D1/2kpn-fo (SEQ ID NO: 20)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D2,1/2, is given as SEQ ID NO:29.

The Phagemid vector pD2D4tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D2D4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D4kpn-fo (SEQ ID NO: 22)) into a Sfi I and Kpn I cut vector, psktripB using standard procedures. Outlines of the resulting nucleotide sequence of D2D4, is given as SEQ ID NO:30.

The Phagemid vector pD2I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D2kpn-fo (SEQ

ID NO: 12)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D2, is given as SEQ ID NO:25.

The Phagemid vector pD2,1/6I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1/6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D1/6kpn-fo (SEQ ID NO: 14)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D2,1/6, is given as SEQ ID NO:26.

The Phagemid vector pD2,1/4I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1/4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D1/4kpn-fo (SEQ ID NO: 16)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D2,1/4, is given as SEQ ID NO:27.

The Phagemid vector pD2,1/3I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1/3 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D1/3kpn-fo (SEQ ID NO: 18)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D2,1/3, is given as SEQ ID NO:28.

The Phagemid vector pD2,1/2I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D1/2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D1/2kpn-fo (SEQ ID NO: 20)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard

procedures. Outlines of the resulting nucleotide sequence of D2,1/2, is given as SEQ ID NO:29.

The Phagemid vector pD2D4I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment D2D4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers D2-rev (SEQ ID NO: 24) and D4kpn-fo (SEQ ID NO: 22)) into a Sfi I and Kpn I cut vector, pskl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of D2D4, is given as SEQ ID NO:30.

Cloning of TNFRSF1B (TNFRII) receptor fragments into expression vectors

The expression vector pT7H6FXD1D2tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D2kpn-fo (SEQ ID NO: 12)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2, is given as SEQ ID NO:32.

The expression vector pT7H6FXD1D2,1/6tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D1/6kpn-fo (SEQ ID NO: 14)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2,1/6, is given as SEQ ID NO:33.

The expression vector pT7H6FXD1D2,1/4tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D1/4kpn-fo (SEQ ID NO: 16)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using

standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2,1/4, is given as SEQ ID NO:34.

The expression vector pT7H6FXD1D2,1/3tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/3 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D1/3kpn-fo (SEQ ID NO: 18)) into a BamH I and Kpn I cut vector, pT7H6-bktripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2,1/3, is given as SEQ ID NO:35.

The expression vector pT7H6FXD1D2,1/2tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D1/2kpn-fo (SEQ ID NO: 20)) into a BamH I and Kpn I cut vector, pT7H6-bktripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2,1/2, is given as SEQ ID NO:36.

The expression vector pT7H6FXD1D4tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment FXD1D4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D4kpn-fo (SEQ ID NO: 22)) into a BamH I and Kpn I cut vector, pT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D4, is given as SEQ ID NO:37.

The expression vector pT7H6FXD2tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D2kpn-fo (SEQ ID NO: 12)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard

procedures. Outlines of the resulting nucleotide sequence of FXD2, is given as SEQ ID NO:39.

The expression vector pT7H6FXD2,1/6tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1/6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) bamD2-rev (SEQ ID NO: 38) and D1/6kpn-fo (SEQ ID NO: 14)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD2,1/6, is given as SEQ ID NO:40.

The expression vector pT7H6FXD2,1/4tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D1/4kpn-fo (SEQ ID NO: 16)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD2,1/4, is given as SEQ ID NO:41.

The expression vector pT7H6FXD2,1/3tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/3 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D1/3kpn-fo (SEQ ID NO: 18)) into a BamH I and Kpn I cut vector, pT7H6-bktripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD2,1/3, is given as SEQ ID NO:42.

The expression vector pT7H6FXD2,1/2tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1/2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D1/2kpn-fo (SEQ ID NO: 20)) into a BamH I and Kpn I cut vector, pT7H6-bktripB using

standard procedures. Outlines of the resulting nucleotide sequence of FXD2,1/2, is given as SEQ ID NO:43.

The expression vector pT7H6FXD2D4tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment FXD2D4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D4kpn-fo (SEQ ID NO: 22)) into a BamH I and Kpn I cut vector, pT7H6-bktripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD2D4, is given as SEQ ID NO:44.

The expression vector pT7H6FXD1D2I10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D2kpn-fo (SEQ ID NO: 12)) into a BamH I and Kpn I cut vector, PT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2, is given as SEQ ID NO:32.

The expression vector pT7H6FXD1D2,1/6I10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D1/6kpn-fo (SEQ ID NO: 14)) into a BamH I and Kpn I cut vector, PT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2,1/6, is given as SEQ ID NO:33.

The expression vector pT7H6FXD1D2.1/4I10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D1/4kpn-fo (SEQ ID NO: 16)) into a BamH I and Kpn I cut vector, PT7H6-

bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2,1/4, is given as SEQ ID NO:34.

The expression vector pT7H6FXD1D2,1/3l10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/3 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D1/3kpn-fo (SEQ ID NO: 18)) into a BamH I and Kpn I cut vector, pT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2,1/3, is given as SEQ ID NO:35.

The expression vector pT7H6FXD1D2,1/2l10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D1/2kpn-fo (SEQ ID NO: 20)) into a BamH I and Kpn I cut vector, pT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D2,1/2, is given as SEQ ID NO:36.

The expression vector pT7H6FXD1D4l10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment FXD1D4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD1-rev (SEQ ID NO: 31) and D4kpn-fo (SEQ ID NO: 22)) into a BamH I and Kpn I cut vector, pT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD1D4, is given as SEQ ID NO:37.

The expression vector pT7H6FXD2l10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D2kpn-fo (SEQ ID NO: 12)) into a BamH I and Kpn I cut vector, PT7H6-bkl10tripB using

standard procedures. Outlines of the resulting nucleotide sequence of FXD2, is given as SEQ ID NO:39.

The expression vector pT7H6FXD2,1/6I10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1/6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D1/6kpn-fo (SEQ ID NO: 14)) into a BamH I and Kpn I cut vector, PT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD2,1/6, is given as SEQ ID NO:40.

The expression vector pT7H6FXD2,1/4I10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D1/4kpn-fo (SEQ ID NO: 16)) into a BamH I and Kpn I cut vector, PT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD2,1/4, is given as SEQ ID NO:41.

The expression vector pT7H6FXD2,1/3I10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1D1/3 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D1/3kpn-fo (SEQ ID NO: 18)) into a BamH I and Kpn I cut vector, pT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD2,1/3, is given as SEQ ID NO:42.

The expression vector pT7H6FXD2,1/2I10tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXD1/2 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D1/2kpn-fo (SEQ ID NO: 20)) into a BamH I and Kpn I cut vector, pT7H6-bkl10tripB

using standard procedures. Outlines of the resulting nucleotide sequence of FXD2,1/2, is given as SEQ ID NO:43.

The expression vector pT7H6FXD2D4I10tripB, is constructed by ligation of the Sfi I and Kpn I restricted DNA fragment FXD2D4 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bamD2-rev (SEQ ID NO: 38) and D4kpn-fo (SEQ ID NO: 22)) into a BamH I and Kpn I cut vector, pT7H6-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence of FXD2D4, is given as SEQ ID NO:44.

The expression vector pT7AD1D4-I162-tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment AD1D4-I162 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers pBamHI-A5 (SEQ ID NO:82) and pKpnI-I162 (SEQ ID NO:83) into a BamH I and Kpn I cut vector, pT7-bktripB using standard procedures. Outlines of the resulting nucleotide sequence AD1D4-I162-tripB, is given as SEQ ID NO:84.

The expression vector pT7AD1D4-GSS-tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment AD1D4-GSS amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers pBamHI-A5 (SEQ ID NO:82) and pKpnI-GSS (SEQ ID NO:85) into a BamH I and Kpn I cut vector, pT7-bktripB using standard procedures. Outlines of the resulting nucleotide sequence AD1D4-GSS-tripB, is given as SEQ ID NO:86.

The expression vector pT7AD1D4-D235-tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment AD1D4-D235 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers pBamHI-A5 (SEQ ID NO:82) and pKpnI-D235 (SEQ ID NO:87) into a BamH I and Kpn I cut vector, pT7-bktripB using

standard procedures. Outlines of the resulting nucleotide sequence AD1D4-D235-tripB, is given as SEQ ID NO:88.

The expression vector pT7AD1D4-I162-I10-tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment AD1D4-I162 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers pBamHI-A5 (SEQ ID NO:82) and pKpnI-I162 (SEQ ID NO:83) into a BamH I and Kpn I cut vector, PT7-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence AD1D4-I162-I10-tripB, is given as SEQ ID NO:89.

The expression vector pT7AD1D4-GSS-I10-tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment AD1D4-GSS amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers pBamHI-A5 (SEQ ID NO:83) and pKpnI-GSS (SEQ ID NO:85) into a BamH I and Kpn I cut vector, PT7-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence AD1D4-GSS-I10-tripB is given as SEQ ID NO:90.

The expression vector pT7AD1D4-D235-I10-tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment AD1D4-D235 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers pBamHI-A5 (SEQ ID NO:83) and pKpnI-D235 (SEQ ID NO:87) into a BamH I and Kpn I cut vector, PT7-bkl10tripB using standard procedures. Outlines of the resulting nucleotide sequence AD1D4-D235-I10-tripB, is given as SEQ ID NO:91.

The expression vector pT7AD1D4-GSS-V17-tripB, is constructed by ligation of the Kpn I and Hind III restricted DNA fragment V17-TripB amplified from cDNA (with the oligonucleotide primers pKpnI-V17 (SEQ ID NO:92) and pBAD6H (SEQ ID NO:93) into a Kpn I and Hind III cut vector, pT7AD1D4-GSS-tripB using standard procedures. Outlines of the resulting nucleotide sequence AD1D4-GSS-V17-tripB, is given as SEQ ID NO:94.

The expression vector pT7AD1D4-D235-V17-tripB, is constructed by ligation of the Kpn I and Hind III restricted DNA fragment V17-TripB amplified from cDNA (with the oligonucleotide primers pKpnI-V17 (SEQ ID NO:92) and pBAD6H (SEQ ID NO:93) into a Kpn I and Hind III cut vector, pT7AD1D4-D235-tripB using standard procedures. Outlines of the resulting nucleotide sequence AD1D4-D235-V17-tripB, is given as SEQ ID NO:95.

Example 3

Production, refolding and purification of trimerised TNFRII fragment AD1D4-GSS-I10-TripB

Construction of the T7 RNA polymerase dependent expression plasmid pT7D1D4GSSI10 (expressing the TNFRII derivative AD1D4-GSS-I10-TripB) is described above in Example 2.

Trimerised human TNFRII fragment AD1D4-GSS-I10 (SEQ ID NO:109) was produced by growing and expressing the plasmid pT7AD1D4-GSS-I10 in *E. coli* BL21 cells in a medium scale (6 x 1 litre) as described by Studier and Moffat, J. Mol. Biol., 189: 113-130, 1986. Briefly, exponentially growing cultures at 37°C were at OD600 0.8 infected with bacteriophage λ -CE6 at a multiplicity of approximately 5. Cultures were grown at 37°C for another three hours before cells were harvested by centrifugation. Cells were lysed by osmotic shock and sonification and total cellular protein extracted into phenol (adjusted to pH 8 with Trisma base). Protein was precipitated from the phenol phase by addition of 2.5 volumes of ethanol and centrifugation. The protein pellet was dissolved in a buffer containing 6 M Guanidinium chloride, 50 mM Tris-HCl pH 8 and 50 mM dithioerythriol. Following gel filtration on Sephadex G-25 (Amersham Biosciences) into 8 M Urea, 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 5 mM 2-mercaptoethanol the crude protein preparation was applied to Ni²⁺ activated NTA-agarose (Qiagen, Germany) columns for purification (Hochuli et al., 1988) of the fusion proteins and, while immobilised on the column, to undergo the cyclic folding procedure as previously described in WO 94/18227.

All buffers prepared for liquid chromatography were degassed under vacuum prior to addition of reductant and/or use.

Upon application of the crude protein extracts on the Ni^{2+} NTA-agarose column, the fusion protein, AD1D4-GSS-I10, was purified from the majority of coli and λ phage proteins by washing with one column volume of the loading buffer followed by 6 M Guanidinium chloride, 50 mM Tris-HCl, and 5 mM 2-mercaptoethanol until the optical density (OD) at 280 nm of the column eluate was stable.

The fusion proteins were refolded on the Ni^{2+} NTA-agarose column using a gradient manager profile as described in Table 1 and 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 2 mM/0.2 mM reduced/oxidized glutathione as buffer A and 8 M urea, 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 3 mM reduced glutathione as buffer B.

After completion of the cyclic folding procedure the AD1D4-GSS-I10 fusion protein was eluted from the Ni^{2+} NTA-agarose columns with a buffer containing 8 M Urea, 0.5 M NaCl, 50 mM Tris-HCl, and 10 mM EDTA pH 8.

Monomeric AD1D4-GSS-I10 fusion proteins were purified from di-mer and higher order multimers by ion exchange chromatography on S- and Q-Sepharose (AmershamBiosciences): The fusion protein eluted by the elution buffer (approximately 80 % of the fusion protein material) was gelfiltrated into a buffer containing 8 M Urea, 10 mM Tris-HCl pH 8.0 and 25 mM NaCl on Sephadex G-25 and applied onto the S-Sepharose ion exchange column. The non-binding protein in the "run through" fractions were directly loaded onto the Q-Sepharose column. Monomeric AD1D4-GSS-I10 fusion proteins were eluted from the Q-Sepharose column with a liner gradient from 8 M Urea, 25 mM NaCl, 10 mM Tris-Hcl pH 8 to 8 M Urea, 300 mM NaCl, 10 mM Tris-Hcl pH 8 over 10 column volumes. Monomeric AD1D4-GSS-I10 fusion protein eluted in the very beginning of the gradient, whereas dimers and higher order multimers eluted later. Fractions containing the monomeric fusion protein were renatured and trimerised by gelfiltration into a buffer containing 10 mM HEPES pH 7.4 and 125 mM NaCl.

TABLE 3: Buffer Gradient manager profile

Step	Time (min)	Flow (ml/min)	Pump A (%)	Pump B (%)
1	0.0	2.00	100.0	0.0
2	45.0	2.00	100.0	0.0
3	46.0	2.00	0.0	100.0
4	52.0	2.00	0.0	100.0
5	60.0	2.00	100.0	0.0
6	105.0	2.00	100.0	0.0
7	106.0	2.00	4.0	96.0
8	113.0	2.00	4.0	96.0
9	120.0	2.00	100.0	0.0
10	165.0	2.00	100.0	0.0
11	166.0	2.00	6.0	94.0
12	172.0	2.00	6.0	94.0
13	180.0	2.00	100.0	0.0
14	225.0	2.00	100.0	0.0
15	226.0	2.00	8.0	92.0
16	232.0	2.00	8.0	92.0
17	240.0	2.00	100.0	0.0
18	285.0	2.00	100.0	0.0
19	286.0	2.00	10.0	90.0
20	292.0	2.00	10.0	90.0
21	300.0	2.00	100.0	0.0
22	345.0	2.00	100.0	0.0
23	346.0	2.00	12.0	88.0
24	352.0	2.00	12.0	88.0
25	360.0	2.00	100.0	0.0
26	405.0	2.00	100.0	0.0
27	406.0	2.00	14.0	86.0
28	412.0	2.00	14.0	86.0
29	420.0	2.00	100.0	0.0
30	465.0	2.00	100.0	0.0
31	466.0	2.00	16.0	84.0
32	472.0	2.00	16.0	84.0
33	480.0	2.00	100.0	0.0
34	525.0	2.00	100.0	0.0

Step	Time (min)	Flow (ml/min)	Pump A (%)	Pump B (%)
35	526.0	2.00	18.0	82.0
36	532.0	2.00	18.0	82.0
37	540.0	2.00	100.0	0.0
38	585.0	2.00	100.0	0.0
39	586.0	2.00	20.0	80.0
40	592.0	2.00	20.0	80.0
41	600.0	2.00	100.0	0.0
42	645.0	2.00	100.0	0.0
43	646.0	2.00	22.0	78.0
44	652.0	2.00	22.0	78.0
45	660.0	2.00	100.0	0.0
46	705.0	2.00	100.0	0.0
47	706.0	2.00	24.0	76.0
48	713.0	2.00	24.0	76.0
49	720.0	2.00	100.0	0.0
50	765.0	2.00	100.0	0.0
51	766.0	2.00	25.0	75.0
52	772.0	2.00	25.0	75.0
53	780.0	2.00	100.0	0.0
54	825.0	2.00	100.0	0.0
55	826.0	2.00	25.0	75.0
56	832.0	2.00	25.0	75.0
57	840.0	2.00	100.0	0.0
58	885.0	2.00	100.0	0.0
59	886.0	2.00	25.0	75.0
60	892.0	2.00	25.0	75.0
61	900.0	2.00	100.0	0.0
62	945.0	2.00	100.0	0.0
63	946.0	2.00	25.0	75.0
64	952.0	2.00	25.0	75.0
65	960.0	2.00	100.0	0.0
66	1005.0	2.00	100.0	0.0
67	1006.0	2.00	30.0	70.0
68	1012.0	2.00	30.0	70.0
69	1020.0	2.00	100.0	0.0
70	1065.0	2.00	100.0	0.0
71	1066.0	2.00	30.0	70.0

Step	Time (min)	Flow (ml/min)	Pump A (%)	Pump B (%)
72	1072.0	2.00	30.0	70.0
73	1080.0	2.00	100.0	0.0
74	1125.0	2.00	100.0	0.0
75	1126.0	2.00	35.0	65.0
76	1132.0	2.00	35.0	65.0
77	1140.0	2.00	100.0	0.0
78	1185.0	2.00	100.0	0.0
79	1186.0	2.00	40.0	60.0
80	1192.0	2.00	40.0	60.0
81	1200.0	2.00	100.0	0.0
82	1245.0	2.00	100.0	0.0
83	1246.0	2.00	50.0	50.0
84	1252.0	2.00	50.0	50.0
85	1260.0	2.00	100.0	0.0
86	1305.0	2.00	100.0	0.0
87	1306.0	2.00	60.0	40.0
88	1312.0	2.00	60.0	40.0
89	1319.0	2.00	100.0	0.0
90	1364.0	2.00	100.0	0.0
91	1365.0	2.00	60.0	40.0
92	1371.0	2.00	60.0	40.0
93	1378.0	2.00	100.0	0.0
94	1423.0	2.00	100.0	0.0

Example 4

Biological activity of trimerised TNFRII fragment AD1D4-GSS-I10

The biological activity of trimerised TNFRII fragment AD1D4-GSS-I10 (produced as described in Example 3) was measured in a L929 cell assay for determining the inhibition of TNF alpha mediated cytotoxicity.

The murine fibroblast cell line L929 (ECACC no.: 85011425) was used to measure TNF alpha mediated cytotoxicity. Cells were maintained in RPMI 1640 liquid medium (Biowhittaker, UK) supplemented with 10% FBS, and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin). The cells were plated into 96-well flat-bottom microtiter

plates (NUNC, Roskilde, Denmark) at 3×10^5 cells/ml and 75 μ l/well of complete RPMI 1640 medium and cultured overnight at 37°C in 5% CO₂. Recombinant human TNF alpha (rhTNFa, RD Systems, UK) (1 ng/ml and 0.1 ng/ml) was incubated with various concentrations (10-fold dilutions) of trimerised receptorfragment (AD1D4-GSS-I10) in complete RPMI 1640 medium supplemented with 2 μ g/ml actinomycin D (Sigma) for 1 hr at 37°C in 5% CO₂. Hereafter, 75 μ l/well of the TNF-alpha/trimerised receptorfragment mixtures were added to the cell culture for overnight incubation at 37°C in 5% CO₂. Each concentration of the TNF-alpha / receptorfragment mixture was tested in triplicate. Cell proliferation was determined using MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-di-phenyl-tetrazolium bromide) as part of the CellTiter 96 Non-Radioactive Cell Proliferation Assay Kit (Promega). For the preparation of reagents sufficient for one 96 well plate containing cells cultured in a 150 μ l volume, 3.0 ml of MTS Solution was added to 150 μ l of PMS. 30 μ l/well of the combined MTS/PMS solution was added and the plates were incubated 1-4 hr at 37°C in 5% CO₂ before recording the absorbance at 492 nm using an ELISA plate reader. Controls of TNF alpha with the cells, cells alone and buffer control were also included in each assay.

The result of the experiment is summarised in Fig. 4. The cytotoxic effect of TNF alpha was significantly inhibited in the presence of the highest concentration of AD1D4-GSS-I10 thus demonstrating biological activity of the compound.

Example 5

Design, construction and production of a trimeric TNF binder using D2E7 antibody fragments.

Single chain antibody variable region fragments (scFv) of the humanised antibody D2E7 is selected as binders in the construction of a trimeric polypeptide capable of binding TNF. The trimeric binder may be constructed by amplifying the VH and VL domains of D2E7, based on the sequence disclosed in US 6,090,382.

Design and construction of trimeric D2E7 scFv with a Gly,Thr linker between N-terminal scFv and C-terminal trimerising domain

The expression vector pT7H6FXD2E7tripB is constructed in two steps. The first step is the construction of pT7H6FX (D2E7VH)tripB. This vector is constructed by ligation of the Bgl II and Kpn I restricted DNA fragment FX(D7E2VH) amplified from DNA containing the sequence of D2E7 (with the oligonucleotide primers FXVH (SEQ ID NO: 45) and VHBamKpn (SEQ ID NO: 46)) into a BamH I Kpn I cut pT7H6bktripB vector. The second step is the construction of pT7H6FXD2E7tripB by ligation of the BamH I Kpn I restricted DNA fragment G4SVL amplified from DNA containing the sequence of D2E7 (with the oligonucleotide primers G4SVL (SEQ ID NO: 47) and VLkpn (SEQ ID NO: 48)) into a BamH I Kpn I cut pT7H6FX(D2E7VH)tripB. The nucleotide sequence of FXD2E7, is given as SEQ ID NO:49.

Design and construction of trimeric D2E7 scFv with a Gly, Gly, Gly, Gly, Ser, Gly, Thr linker between N-terminal scFv and C-terminal trimerising domain

The expression vector pT7H6FXD2E7G4StripB is constructed in two steps. The first step is the construction of pT7H6FX(D2E7VH)tripB by ligation of the Bgl II and Kpn I restricted DNA fragment FX(D7E2VH) amplified from DNA containing the sequence of D2E7 (with the oligonucleotide primers FXVH (SEQ ID NO: 45) and VHBamKpn (SEQ ID NO: 46)) into a BamH I Kpn I cut pT7H6bktripB vector. The second step is the construction of pT7H6FXD2E7tripB by ligation of the BamH I Kpn I restricted DNA fragment G4SVL amplified from DNA containing the sequence of D2E7 (with the oligonucleotide primers G4SVL (SEQ ID NO: 47) and VLG4Skpn (SEQ ID NO: 50)) into a BamH I Kpn I cut pT7H6FX(D2E7VH)tripB. The resulting nucleotide sequence of FXD2E7G4S, is given as SEQ ID NO:51.

Design and construction of trimeric D2E7 scFv with Gly, Ser linker between the N-terminal trimerising domain and the C-terminal scFv

The Expression vector pT76HFXTripAGSD2E7, is constructed by ligation of the Bcl I and Hind III restricted DNA fragment amplified from pT7H6FXD2E7G4StripB (with the oligonucleotide primers bclVH (SEQ ID NO:52) and VLhind (SEQ ID: 53)) into a BamH I and Hind III cut vector, pT76HFXtripa (Loretsen, RH. et al, Biochem J.;347:83-87,

2000) using standard procedures. The resulting nucleotide sequence of GSD2E7, is given as SEQ ID NO:54.

Design and construction of trimeric D2E7 scFv with Gly, Ser, Gly, Gly, Gly, Gly, Ser linker between the N-terminal trimerising domain and the C-terminal scFv

The Expression vector pT76HFXTripAG4SD2E7, is constructed by ligation of the Bcl I and Hind III restricted DNA fragment amplified from pT7H6FXD2E7G4StripB (with the oligonucleotide primers bclG4SVH (SEQ ID NO:55) and VLhind (SEQ ID: 53)) into a BamH I and Hind III cut vector, pT76HFXtripa (Lorentsen, RH. et al, Biochem J.;347:83-87, 2000) using standard procedures. The resulting nucleotide sequence of G4SD2E7, is given as SEQ ID NO:56.

To prepare the above fusion proteins H6FXD2E7tripB, H6FXD2E7G4StripB, H6FXTripAD2D7TripA and H6FxTripAG4SD2E7, the plasmids pT7H6FXD2E7tripB, pT7H6FXD2E7G4StripB, pT7H6FXTripAD2D7TripA and pT7H6FxTripAG4SD2E7 is grown in small scale (1 litre; 2xTY medium, 5 mM MgSO₄ and 100 µg ampicillin) in *E. coli* BL21 cells, as described by Studier et al. (1990). Exponentially growing cultures at 37°C are at OD₆₀₀ 0.8 infected with bacteriophage lambda CE6 at a multiplicity of approximately 5. Cultures are grown at 37°C for another three hours and the cells harvested by centrifugation. Cells are re-suspended in 50 ml of 0.5 M NaCl, 50 mM Tris-HCl pH 8, and 1 mM EDTA pH 8. Phenol (50 ml adjusted to pH 8) is added to each and the mixtures are sonicated to extract total protein. After clarification by centrifugation (25 minutes at 10.000 g) crude protein fractions are precipitated from the phenol phases by addition of 2.5 volumes of ethanol and centrifugation. Protein pellets are dissolved in a buffer (15-25 ml) containing 6 M guanidinium chloride, 50 mM Tris-HCl pH 8 and 0.1 M dithioerythriol. Following gel filtration on Sephadex G-25 (Pharmacia, Sweden) into 8 M Urea, 1M NaCl, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol, the crude protein preparations are applied to Ni activated NTA-agarose columns (75 ml column volume) for purification (Hochuli et al., 1988). Washing buffer (6 M guanidine-HCl, 50 mM Tris-HCl pH 8 and 10 mM 2-mercaptoethanol) is then flowed through the columns until stable baselines are obtained.

Virtually pure fusion proteins are then eluted by applying a pH gradient to each column (1000 ml gradient in 8 M urea and 10 mM 2-mercaptoethanol obtained by linear (per volume) mixing of solutions containing 50 mM sodium di-hydrogenphosphate (pH 5 buffer) and 50 mM di-sodium hydrogenphosphate (pH 8 buffer).

In preparation for in vitro refolding by the method of Thøgersen et al. (WO 94/18227) 20 mg of each purified fusion protein are mixed in suspensions in refolding "buffer B" (described below) with aliquots of suspensions of Ni^{2+} activated NTA-agarose matrix sufficient to generate columns of about 75 ml packed bed volume. Each fusion protein is then subjected to the iterative refolding procedure as described for plasminogen kringle 4 in WO 94/18227, except that refolding of the scFv containing fusion proteins is carried out at 10°C using a buffer containing 0.5 M NaCl, 50 mM Tris-HCl pH 8, 2 mM glutathione and 0.2 mM oxidized glutathione as "buffer A" and a buffer containing 8 M urea, 1 M NaCl, 50 mM Tris-HCl pH 8 and 2 mM glutathione as "buffer B".

After completion of the refolding procedure each column is washed with 300 ml buffer containing 0.5 M NaCl and 50 mM Tris-HCl pH 8 to wash away glutathione. The refolded fraction of each protein is then eluted from the NTA-agarose in 20 mM EDTA, 0.5 M NaCl and 50 mM Tris-HCL pH 8 to the elution buffer. After addition of solid urea to achieve a final concentration of about 8 M to each protein sample and dilution or dialysis to reduce NaCl concentrations to below 5 mM, final purification of each correctly folded fusion protein product is then accomplished by ion exchange chromatography (S-Sepharose, Pharmacia, 1,6 (i.d.) by 90 centimeter column in a buffer containing 8 M urea, 5 mM Tris-HCl (from 1 M stock solution at pH 8) and 25 mM sodium acetate (from 1 M stock solution at pH 5), eluted at 2 ml/min). After dialysis against aqueous buffers (e.g. phosphate buffered saline) each pure and correctly refolded fusion protein is recovered in yields of 2-6 mg per litre of culture grown.

Example 6

Design and construction of a trimeric APRIL binder using TNFRSF13B receptor fragments

The APRIL receptor TNFRSF13B is used for the construction of trimeric binders against the trimeric cytokine APRIL, and based on the trimerising domain TripB derived from tetranectin. The design and cloning of such binders with different linkers is outlined in the following:

Cloning of TNFRSF13B6

The expression vector pT7H6FXTNFRS13B6tripB, is constructed in two steps. The first step is to construct pT7H6FX?TNFSF13B by ligation of the Bgl II and Kpn I restricted DNA fragment FX?TNFRSF13B amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bgliiFX?TNFRSF13B (SEQ ID NO: 57) and ?TNFRSF13Bkpn: (SEQ ID NO: 58)) into a BamH I and Kpn I cut vector, pT7H6-bktripB using standard procedures. The second step is to construct the final expression vector pT7H6FXTNFRSF13B6tripB by ligation of the Kpn I restricted DNA fragment ?TNFRSF13B6 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers kpn?TNFSF13B (SEQ ID NO: 59) and ?TNFSF13B6kpn (SEQ ID NO: 60)) into a Kpn I cut pT7H6FX?TNFSF13B vector, using standard procedures. The resulting nucleotide sequence of FXTNFRSF13B6, is given as SEQ ID NO:61.

Cloning of TNFRSF13B10

The expression vector pT7H6FXTNFRS13B10tripB, is constructed in two steps. First step is to construct pT7H6FX?TNFRSF13B by ligation of the Bgl II and Kpn I restricted DNA fragment FX?TNFRSF13B amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bgliiFX?TNFRSF13B (SEQ ID NO: 57) and ?TNFRSF13Bkpn (SEQ ID NO: 58)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. The second step is to construct the final expression vector pT7H6FXTNFRSF13B10tripB by ligation of the Kpn I restricted DNA

fragment ?TNFSF13B10 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers kpn?TNFSF13B (SEQ ID NO: 59) and ?TNFSF13B10kpn (SEQ ID NO: 62)) into a Kpn I cut pT7H6FX?TNFRSF13B vector, using standard procedures. The resulting nucleotide sequence of FXTNFRSF13B10, is given as SEQ ID NO: 63.

Cloning of TNFRSF13B20

The expression vector pT7H6FXTNFRS13B20tripB, is constructed in two steps. First step is to construct pT7H6FX?TNFRSF13B by ligation of the Bgl II and Kpn I restricted DNA fragment FX?TNFSF13B amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bgliiFX?TNFRSF13B (SEQ ID NO: 57) and ?TNFRSF13Bkpn (SEQ ID NO: 58)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. The second step is to construct the final expression vector pT7H6FXTNFRSF13B20tripB by ligation of the Kpn I restricted DNA fragment ?TNFSF13B20 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers kpn?TNFRSF13B (SEQ ID NO: 59) and ?TNFRSF13B20kpn (SEQ ID NO: 64)) into a Kpn I cut pT7H6FX?TNFRSF13B vector, using standard procedures. The resulting nucleotide sequence of FXTNFRSF13B20, is given as SEQ ID NO:65.

Cloning of TNFRSF13B30

The expression vector pT7H6FXTNFRS13B30tripB, is constructed in two steps. First step is to construct pT7H6FX?TNFRSF13B by ligation of the Bgl II and Kpn I restricted DNA fragment FX?TNFRSF13B amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bgliiFX?TNFRSF13B (SEQ ID NO: 57) and ?TNFRSF13Bkpn (SEQ ID NO: 58)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. The second step is to construct the final expression vector pT7H6FXTNFRSF13B30tripB by ligation of the Kpn I restricted DNA fragment ?TNFRSF13B30 amplified from cDNA, isolated from a mixture of human

bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers kpn?TNFRSF13B (SEQ ID NO: 59) and ?TNFRSF13B30kpn (SEQ ID NO: 66)) into a Kpn I cut pT7H6FX?TNFRSF13B vector, using standard procedures. The resulting nucleotide sequence of FXTNFRSF13B30, is given as SEQ ID NO:67.

Cloning of TNFRSF13B61

The expression vector pT7H6FXTNFRSF13B61tripB, is constructed in two steps. First step is to construct pT7H6FX?TNFRSF13B by ligation of the Bgl II and Kpn I restricted DNA fragment FX?TNFRSF13B amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers bgliiFX?TNFRSF13B (SEQ ID NO: 57) and ?TNFRSF13Bkpn (SEQ ID NO: 58)) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. The second step is to construct the final expression vector pT7H6FXTNFRSF13B61tripB by ligation of the Kpn I restricted DNA fragment ?TNFRSF13B61 amplified from cDNA, isolated from a mixture of human bone marrow and human leukocyte (Clontech Laboratories, Inc cat # 7181-1 and 7182-1) (with the oligonucleotide primers kpn?TNFRSF13B (SEQ ID NO: 59) and ?TNFRSF13B61kpn (SEQ ID NO: 68)) into a Kpn I cut pT7H6FX?TNFRSF13B vector, using standard procedures. The resulting nucleotide sequence of FXTNFRSF13B61, is given as SEQ ID NO:69.

Example 7

Design and construction of a trimeric TWEAK binder using TNFRSF Fn14 receptor fragments

The TWEAK receptor TNFRSF Fn14 is used for the construction of a trimeric binder against the trimeric cytokine TWEAK, and based on the trimerising domain TripB derived from tetranectin. The design and cloning of the binder is outlined in the following:

The expression vector pT7H6FXFn14tripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXFn14 amplified from cDNA, isolated from human heart (Clontech Laboratories, Inc cat # 7121-1) (with the oligonucleotide primers bamFn-rev (SEQ ID NO: 70) and FNkpn-fo (SEQ ID NO:71) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. Outlines of the resulting the nucleotide sequence of FXFn14, is given as SEQ ID NO:72.

Example 8

Design and construction of a trimeric BAFF binder using TNFRSF13C receptor fragments

The BAFF receptor TNFRSF13B is used for the construction of a trimeric binder against the corresponding trimeric cytokine BAFF, and based on the trimerising domain TripB derived from tetranectin. The design and cloning of the binder is outlined in the following:

Cloning of trimeric TNFRSF13C fragment

The expression vector pT7H6FXTNFSF13CtripB, is constructed by ligation of the BamH I and Kpn I restricted DNA fragment FXTNFSF13C amplified from cDNA, isolated from human Lymph Node(Clontech Laboratories, Inc cat # 7164-1) (with the oligonucleotide primers bam13C-rev (SEQ ID NO: 73) and 13Ckpn-fo (SEQ ID NO:74) into a BamH I and Kpn I cut vector, PT7H6-bktripB using standard procedures. Outlines of the resulting the nucleotide sequence of FXTNFSF13C, is given as SEQ ID NO:75.

Example 9

Isolation and construction of trimerised CTLD binders for TNF

The scaffold structure of Tetranectin (SEQ ID NO:96) C-type lectin-like domains (CTLD), as previously disclosed in WO/0248189, was used for the isolation and construction of a trimeric binding units for the trimeric cytokine TNF (TNF alpha). The design and cloning of the binding units is outlined in the following:

Library construction and primary selection

Phage display was used to isolate TNF CTLD binders. The phage display libraries used were based on the monovalent CTLD format of tetranectin (SEQ ID NO:97). The combinatorial library PhtCTLD-lb003 (WO/0248189, Example 5) and a variant of this library made essential as PhtCTLD-lb003, but including two additional randomised oligonucleotides for loop 1: TN-lib3-tprev, randomised in tetranectin (SEQ ID NO:98) amino acid residue positions 116-122 and TN-lib2-tprev (SEQ ID NO: 99) and 2 additional oligonucleotides for loop 4: TN-lib3-tpfo, randomised in position 146-149 (SEQ ID NO:100) and TN-lib2-tpfo (SEQ ID NO:101) in the assembly reaction. Two rounds of selection were performed using approximately 1×10^{12} phage as input and 10 µg/ml biotinylated-TNF in the first round of panning and 1 µg/ml in the second.

The selections were performed as follows: 20 µl streptavidin-coated paramagnetic beads (Dyna) were washed two times in 1 ml PBS (PBS, 0.2 g KCl, 0.2 g KH_2PO_4 , 8 g NaCl, 1.44 g Na_2HPO_4 , $2\text{H}_2\text{O}$, water to 1 l, and adjusted to pH 7.4 with NaOH), and blocked in 3% non fat dried milk for one hour at room temperature. 250 µl preblocked phage in 3% non fat dried milk/PBS were mixed with 250 µl of soluble biotinylated TNF, and allowed to incubate at 37°C for 30 minutes. After washing the streptavidin beads once in PBS, 0.1% Tween 20 and twice in PBS, these were added to the reaction to capture antigen-bound phage. The beads were extensively washed with PBS, 0.1% Tween 20 and PBS, and antigen bound phage were eluted from the beads with 200 µl 50 mM dithiothreitol for 30 min at room temperature. Eluted phages were reinfected in exponentially growing *E. coli* TG1 cells, before plating and titration on 2xTY agar plates containing 2% glucose and 0.1 mg/ml ampicillin.

Screening of single clones from selected populations by analysis of binding to TNF alpha in ELISA was done essentially as described in WO/0248189, except that antigen used for coat in ELISA was 5µg/ml TNF.

A specific TNF alpha binder, called TN3-2, was isolated from the second round of selection (Table 4).

Secondary library construction and affinity driven selection

It was investigated whether the TNF affinity of TN3-2 could be improved by introducing new sequence variation to TN3-2. For the construction of a library of TN3-2 mutants, the TN3-2 clone was used as a template and subjected to new randomization in loop 4 using the oligonucleotides TN-lib2-tpfo (SEQ ID NO:101) and TN-lib3-tpfo (SEQ ID NO:100) (Lib. TN3-2 loop4 r). The library construction was done essentially as described in WO/0248189.

The TN3-2loop4r library was used in 3 rounds of affinity driven selection with decreasing concentrations of biotinylated TNF (100 ng/ml to 0.1 ng/ml). Selection was done as described above. Screening for positive clones was done as described above.

Results

The sequence of the parental clone TN3-2 was different from tetranectin in loop 1 (Tetranectin amino acids nos. 116-122) and in loop 4 (Tetranectin amino acids nos. 146-149). After three rounds of affinity driven selection on the TN3-2loop4r library, positive clones were identified by ELISA analysis, and 45 out of 48 clones were shown to bind TNF alpha. Loop 1 and loop 4 sequences of a selection of the identified TNF alpha binding clones together with their corresponding SEQ ID NOs are shown in Table 4 (TN3-2-B, TN3-2-C, TN3-2-D).

TABLE 4: Amino acid sequences in loop 1 and loop 4 of the parental clone TN3-2 and three affinity matured clones isolated from the library TN3-2loop4r

Clone	SEQ ID	Loop 1 sequence	Loop 4 sequence	Other mutations ^a
Tetranectin	SEQ ID NO:96	DMAAEGT	GGKT	
TN3-2	SEQ ID NO:102	KVRSRYF	PRHT	V124 to M
TN3-2-B	SEQ ID NO:103	KVRSRYF	PTNN	V124 to M, D165 to G
TN3-2-C	SEQ ID NO:104	KVRSRYF	PTNR	
TN3-2-D	SEQ ID NO:105	KVRSRYF	PNNR	V124 to I, D165 to G

^a Mutations outside the loop 4 sequence in tetranectin.

Example 10

Affinity measurements of trimerised CTLD binders for TNF

The DNA inserts encoding the monomeric CTLD TNF alpha binders isolated as described in Example 7 were subcloned into *E. coli* pBAD expression vector (Invitrogen Corp., USA). The recombinant monomer TNF alpha binders were expressed in *E. coli* and purified from periplasm according to the manufactures instructions. Purified monomers were dialysed into 10 mM Tris pH 8.0, 150 mM NaCl, 2 mM CaCl₂ before analysis on BiaCore.

In order to express the trimeric format of the TNF alpha binders, appropriate DNA inserts encoding the TNF alpha binders (from Example 7) were cleaved with the restriction endonucleases Bgl II and Mun I, and the loop 1 and 4 containing DNA fragment subcloned into Bgl II Mun I restricted *E. coli* pT7H6FX-htlec DNA (as outlined in WO 02/48189, Example 1 and Fig. 5).

The recombinant trimeric TNF alpha binders were expressed in *E. coli* and purification of the unfolded fusion protein derivatives were performed essentially as described in WO 94/18227, Example 9.

Briefly, refolding of the TNF alpha binders were performed by loading the fusion proteins on Ni²⁺-charged nitrilotriacetic acid (NTA) columns in 8 M urea, 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 5 mM 2-mercaptoethanol. After being loaded, the columns were subjected to a cyclic refolding procedure. Refolding buffers used were: renaturation buffer A (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 2 mM CaCl₂, 2 mM reduced glutathione, and 0.2 mM oxidized glutathione) and denaturing buffer B (8 M urea, 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 2 mM CaCl₂, 3 mM reduced glutathione). Refolded fusion proteins were eluted from the columns by 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM EDTA and the fusion proteins were cleaved with bovine blood coagulation factor Xa (Protein Engineering Technology, Aarhus, Denmark) at 1:100 (w/w) at 4°C overnight. The cleaved proteins were taken into a 8 M urea, 25 mM sodium acetate buffer (pH 5), 50 mM NaCl, 1 mM Tris-HCl buffer by gel filtration on Sephadex G25 and loaded on 10 ml SP-Sepharose columns (Amersham Biosciences) and gradient-eluted from 50 mM to 500 M NaCl over 20 column volumes. Fractions

containing cleaved and monomeric protein, as judged by non-reducing SDS/PAGE analysis, were pooled and the buffer was exchanged to 10 mM Tris pH 8.0, 150 mM NaCl, 2 mM CaCl₂ by gel filtration on PD10 columns (Amersham Biosciences).

Surface plasmon resonance (SPR) binding analysis was performed on a BIAcore 3000 instrument (BiaCore, Sweden). TNF alpha capture antibody (AHC3712, Biosource International) to be immobilized was dissolved in 10 mM NaAcetate pH 5.0 and then immobilized on a CM5 BiaCore sensor chip using the Amine Coupling kit (BiaCore, Sweden).

Binding analysis was performed at a flow rate of 5 µl/min. Before loading of the protein sample, the chip was equilibrated in 10 mM Tris pH 8.0, 150 mM NaCl, 2 mM CaCl₂, 50 µM EDTA and 0.005% Surfactant P20. TNF alpha was dissolved in 10 mM Tris pH 8.0, 150 mM NaCl, 2 mM CaCl₂ at 10 µg/mL and 10 µL was injected. Aliquots (20 µl) of TNF alpha binders in monomeric or the trimeric format were injected using the KINJECT option. Five min of dissociation were allowed before the chip was regenerated with 10 mM Glycine pH 2.5. Binding of TNF alpha binders was tested at six different protein concentrations, ranging from 1 to 200 nM. Binding data were evaluated using the BIAevaluation program version 3.2 (BiaCore).

Table 5 shows the kinetic values derived from the BiaCore data. The avidity effect of trimerising the TNF alpha binders TN3-2-B, TN3-2-C, TN3-2-D is seen from the fold increase in affinity moving from the monomeric binders to the corresponding trimeric binders (TN-2-B, TN-2-C and TN-2-D).

TABLE 5

Clone	SEQ ID	$k_{on} M^{-1}s^{-1} *$	$k_{off} s^{-1}$	K_D^{obs}	Fold increase
TN-2-B (trimeric)	SEQ ID NO:106	3.02×10^6	7.36×10^{-4}	~ 0.24 nM	304
TN3-2-B (monomeric)	SEQ ID NO:103	1.4×10^7	0.923	73 nM	n.a.
TN-2-D (trimeric)	SEQ ID NO:107	5.06×10^5	2.07×10^{-3}	4.1 nM	12
TN3-2-D (monomeric)	SEQ ID NO:105	3.64×10^5	0.0185	50 nM	n.a.
TN-2-C (trimeric)	SEQ ID NO:108	8.84×10^5	3.53×10^{-3}	4 nM	37
TN3-2-C (monomeric)	SEQ ID NO:104	1.34×10^5	0.022	150 nM	n.a.

By trimerizing the TNF alpha binders a significant gain in affinity (K_D) is obtained. For example, monomeric TN3-2-B has a very poor k_{off} value. In contrast hereto, the trimeric version of the same CTLD binder (TN-2-B), has a k_{off} value which is improved by over a 1000 fold. In general it can be seen that the off-rates are improved several fold by trimerisation. Moreover, the low affine parental clone TN3-2 of Example 7 could only be measured on BiaCore in its trimeric form, as the monomer had an affinity below detection limit.

References

Studier and Moffat (1986), Journal of Molecular Biology 189: 113-130.

Hochuli, E., Bannwarth, W., Döbeli, H., Gentz, R. and Stüber, D. (1988), Bio/Technology 6:1321-1325.

Loretsen, RH. et al. (2000) Biochemical Journal 347:83-87.

Claims

1. A trimeric polypeptide comprising three monomers, each of said monomers comprising a specific binding member capable of binding a trimeric cytokine, and each of said monomers comprising a trimerising domain.
2. A trimeric polypeptide according to claim 1, wherein the trimeric cytokine is a member of the Tumor necrosis factor ligand superfamily.
3. A trimeric polypeptide according to claim 2, wherein the member of the Tumor necrosis factor ligand superfamily is selected from the group consisting of LTA; TNF; LTβ; TNFSF4; TNFSF5; TNFSF6; TNFSF7; TNFSF8; TNFSF9; TNFSF10; TNFSF11; TNFSF12; TNFSF13; TNFSF13B; TNFSF14; TNFSF15; and TNFSF18.
4. A trimeric polypeptide according to claim 2, wherein the specific binding member is a polypeptide derived from a member of the Tumor necrosis factor receptor superfamily.
5. A trimeric polypeptide according to claim 2, wherein the member of the Tumor necrosis factor receptor superfamily is selected from the group consisting of TNFRSF1A, TNFRSF1B, LTBR, TNFRSF4, TNFRSF5, TNFRSF6, TNFRSF6B, TNFRSF7, TNFRSF8, TNFRSF9, TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D, TNFRSF11A, TNFRSF11B, TNFRSF12, TNFRSF12L, TNFRSF13B, TNFRSF13C, TNFRSF14, TNFRSF14, NGFR, TNFRSF17, TNFRSF18, TNFRSF19, TNFRSF19L, TNFRSF21, TNFRSF22, and TNFRSF23.
6. A trimeric polypeptide according to claim 1, wherein the specific binding member is derived from TNFRSF1A (p55 TNF receptor).
7. A trimeric polypeptide according to claim 1, wherein the specific binding member is derived from TNFRSF1B (p75 TNF receptor).

8. A trimeric polypeptide according to claim 7, wherein the specific binding member is a polypeptide comprising an amino acid sequence selected from the group consisting of TNFRSF1B 1-235 (SEQ ID NO:76), TNFRSF1B 1-185 (SEQ ID NO:77), TNFRSF1B 1-163 (SEQ ID NO:78) and TNFRSF1B 1-142 (SEQ ID NO:79).
9. A trimeric polypeptide according to claim 7, wherein the specific binding member is a polypeptide comprising an amino acid sequence encoded by a DNA sequence selected from the group consisting of TNFRSF1B D1D2 (SEQ ID NO:13), TNFRSF1B D1D2, 1/6 (SEQ ID NO:15), TNFRSF1B D1D2 1/4 (SEQ ID NO:17), TNFRSF1B D1D2, 1/3 (SEQ ID NO:19), TNFRSF1B D1D2, 1/2 (SEQ ID NO:21), TNFRSF1B D1D4 (SEQ ID NO:23), TNFRSF1B D2 (SEQ ID NO:25), TNFRSF1B D2, 1/6 (SEQ ID NO:26), TNFRSF1B D2, 1/4 (SEQ ID NO:27), TNFRSF1B D2, 1/3 (SEQ ID NO:28), TNFRSF1B D2, 1/2 (SEQ ID NO:29) and TNFRSF1B D2D4 (SEQ ID NO:30).
10. A trimeric polypeptide according to claim 1, wherein the specific binding member is an antibody or antibody fragment.
11. A trimeric polypeptide according to claim 10, wherein the antibody or antibody fragment binds to human TNF (SEQ ID NO:80) in at least one region selected from the regions consisting of amino acid residues 1-18, 1-20, 1-26, 1-30, 12-22, 22-31, 22-40, 36-45, 49-97, 49-98, 56-79, 58-65, 69-97, 70-87, 76-90, 96-105, 105-128, 108-128, 110-127, 115-125, 117-128, 132-157, 135-155, 136-153, 138-149, 141-153 and 146-157.
12. A trimeric polypeptide according to claim 11, wherein the antibody or antibody fragment is selected from MAb 1 (ECACC 89080301), MAb 21 (ECACC 90012432), MAb 25 (ECACC 89121401), MAb 32 (ECACC 89080302), MAb 37 (ECACC 89080303), MAb 42 (ECACC 89080304), MAb 47 (ECACC 89121402), MAb 53 (ECACC 90012433) and MAb 54 (ECACC 89083103) or a fragment thereof.
13. A trimeric polypeptide according to claim 10, wherein the antibody is D2E7 or a fragment thereof.

14. A trimeric polypeptide according to claim 9, wherein the antibody is CDP 870 or a fragment thereof.
15. A trimeric polypeptide according to claim 1, wherein the specific binding member is a protein having the scaffold structure of C-type lectin-like domains (CTLTD).
16. A trimeric polypeptide according to claim 15, wherein the specific binding member having the scaffold structure of C-type lectin-like domains is selected from the group consisting of TN3-2-B (SEQ ID NO:103), TN3-2-C (SEQ ID NO:104) and TN3-2-D (SEQ ID NO:105).
17. A trimeric polypeptide according to claim 1, wherein the trimerising domain is derived from tetranectin.
18. A trimeric polypeptide according to claim 17, wherein the trimerising domain derived from tetranectin comprises a sequence having at least 68% amino acid sequence identity with the sequence of SEQ ID NO:81.
19. A trimeric polypeptide according to claim 18, wherein the amino acid sequence identity is at least 75%, such as at least 87% including at least 92%.
20. A trimeric polypeptide according to claim 17, wherein the trimerising domain derived from tetranectin comprises the amino acid sequence SEQ ID NO:81.
21. A trimeric polypeptide according to claim 17, selected from the group consisting of TN-2-B (SEQ ID NO:106), TN-2-C (SEQ ID NO:108), TN-2-D (SEQ ID NO:107), and AD1D4-GSS-I10 (SEQ ID NO:109).
22. A trimeric polypeptide according to claim 1, further comprising a linker between the specific binding member and the trimerising domain.
23. A pharmaceutical composition comprising the trimeric polypeptide according to any of claims 1-22.

24. A method of treating a subject having a pathology mediated by a trimeric cytokine such as a tumor necrosis factor, comprising administering to said subject an effective amount of the trimeric polypeptide according to any of claims 1-22 or the composition according to claim 23.

25. A method according to claim 24 wherein the pathology mediated by tumor necrosis factor is selected from the group consisting of rheumatoid arthritis, psoriasis and Crohn's disease.

26. A method for the preparation of a trimeric polypeptide comprising three monomers, each of said monomers comprising a specific binding member capable of binding a trimeric polypeptide cytokine, and each of said monomers comprising a trimerising domain, said method comprising the steps of (i) culturing a host transformed with a vector encoding said trimeric polypeptide under such conditions that said trimeric polypeptide is expressed; and (ii) isolating said trimeric polypeptide.

27. A method according to claim 26, wherein said specific binding member comprises an amino acid sequence selected from the group consisting of TNFRSF1B 1-235 (SEQ ID NO:76), TNFRSF1B 1-185 (SEQ ID NO:77), TNFRSF1B 1-163 (SEQ ID NO:78) and TNFRSF1B 1-142 (SEQ ID NO:79).

28. A method according to claim 26, wherein the specific binding member is a polypeptide comprising an amino acid sequence encoded by a DNA sequence selected from the group consisting of TNFRSF1B D1D2 (SEQ ID NO:13), TNFRSF1B D1D2, 1/6 (SEQ ID NO:15), TNFRSF1B D1D2 1/4 (SEQ ID NO:17), TNFRSF1B D1D2, 1/3 (SEQ ID NO:19), TNFRSF1B D1D2, 1/2 (SEQ ID NO:21), TNFRSF1B D1D4 (SEQ ID NO:23), TNFRSF1B D2 (SEQ ID NO:25), TNFRSF1B D2, 1/6 (SEQ ID NO:26), TNFRSF1B D2, 1/4 (SEQ ID NO:27), TNFRSF1B D2, 1/3 (SEQ ID NO:28), TNFRSF1B D2, 1/2 (SEQ ID NO:29) and TNFRSF1B D2D4 (SEQ ID NO:30).


29. Use of a trimeric polypeptide according to any of claims 1-22.

30. Use of a trimeric polypeptide according to any of claims 1-22 for the preparation of a pharmaceutical composition.

31. An assay method for detecting a trimeric cytokine in a sample comprising (i) contacting said sample with a trimeric polypeptide according to claim 1, and (ii) detecting the binding of the trimeric polypeptide to the trimeric cytokine.


1/4

Figure 1




2/4

Figure 2




3/4

Figure 3



4/4

Figure 4



SEQUENCE LISTING

<110> Borean Pharma A/S
 <120> Trimeric binding proteins for Trimeric Cytokines
 <130> 3005
 <160> 109
 <170> PatentIn version 3.1
 <210> 1
 <211> 33
 <212> DNA
 <213> Homo sapiens
 <400> 1
 ctgccatgcg gccgccttca gggagaccgt ctg 33
 <210> 2
 <211> 58
 <212> DNA
 <213> Homo sapiens
 <400> 2
 gtgaccaggc ccagccggcc atgtaagtag ctaaggtacc gagccaccaa cccagaag 58
 <210> 3
 <211> 197
 <212> DNA
 <213> Homo sapiens
 <400> 3
 ggcccagccg gccatgtaag tagctaaggt accgagccac caaccagaa gccaagaag 60
 attgtaaattg ccaagaaaga tgttgtgaac acaaagatgt ttgaggagct caagagccgt 120
 ctggacaccc tggcccagga ggtggccctg ctgaaggagc agcaggccct gcagacggtc 180
 tccctgaagg cggccgc 197
 <210> 4
 <211> 62
 <212> DNA
 <213> Homo sapiens
 <400> 4
 gtgaccaggc ccagccggcc atgtaagtag ctaaggtacc attgtaaattg ccaagaaaga 60
 tg 62
 <210> 5
 <211> 170
 <212> DNA
 <213> Homo sapiens
 <400> 5
 ggcccagccg gccatgtaag tagctaaggt accattgtaa atgccaagaa agatgttgtg 60
 aacacaaaga tgtttgagga gctcaagagc cgtctggaca ccctggccca ggaggtggcc 120
 ctgctgaagg agcagcaggc cctgcagacg gtctccctga aggcggccgc 170

<210> 6
<211> 32
<212> DNA
<213> Homo sapiens

<400> 6
ctgccataag cttacttcag ggagaccgtc tg 32

<210> 7
<211> 51
<212> DNA
<213> Homo sapiens

<400> 7
gtgaccagga tccatgtaag tagctaaggt accgagccac caaccagaa g 51

<210> 8
<211> 191
<212> DNA
<213> Homo sapiens

<400> 8
ggatccatgt aagtagctaa ctgcaggtga gccaccaacc cagaagccca agaagattgt 60
aaatgccaaag aaagatgttg tgaacacaaa gatgtttgag gagctcaaga gccgtctgga 120
caccctggcc caggaggtgg ccctgctgaa ggagcagcag gccctgcaga cggctctccct 180
gaagtaagct t 191

<210> 9
<211> 55
<212> DNA
<213> Homo sapiens

<400> 9
gtgaccagga tccatgtaag tagctaaggt accattgtaa atgccaaagaa agatg 55

<210> 10
<211> 162
<212> DNA
<213> Homo sapiens

<400> 10
ggatccatgt aagtagctaa ggtaccattg taaatgccaa gaaagatgtt gtgaacacaa 60
agatgtttga ggagctcaag agccgtctgg acaccctggc ccaggaggtg gccctgctga 120
aggagcagca ggcctgcag acggtctccc tgaagtaagc tt 162

<210> 11
<211> 44
<212> DNA
<213> Homo sapiens

<400> 11
gtgaccaggc ccagccggcc atggccggga gcacatgccg gctc 44

<210> 12

<211> 34
 <212> DNA
 <213> Homo sapiens

<400> 12
 cgtgctgggt accggtgcag atgcggttct gttc 34

<210> 13
 <211> 274
 <212> DNA
 <213> Homo sapiens

<400> 13
 ggcccagccg gccatggccg ggagcacatg ccggctcaga gaatactatg accagacagc 60
 tcagatgtgc tgcagcaagt gctcgccggg ccaacatgca aaagtcttct gtaccaagac 120
 ctccggacacc gtgtgtgact cctgtgagga cagcacatac acccagctct ggaactgggt 180
 tcccagagtgc ttgagctgtg gctcccgctg tagctctgac caggtggaaa ctcaagcctg 240
 cactcgggaa cagaaccgca tctgcaccgg tacc 274

<210> 14
 <211> 39
 <212> DNA
 <213> Homo sapiens

<400> 14
 cgtgctgggt accgggccta gcggtgcaga tgcggttct 39

<210> 15
 <211> 283
 <212> DNA
 <213> Homo sapiens

<400> 15
 ggcccagccg gccatggccg ggagcacatg ccggctcaga gaatactatg accagacagc 60
 tcagatgtgc tgcagcaagt gctcgccggg ccaacatgca aaagtcttct gtaccaagac 120
 ctccggacacc gtgtgtgact cctgtgagga cagcacatac acccagctct ggaactgggt 180
 tcccagagtgc ttgagctgtg gctcccgctg tagctctgac caggtggaaa ctcaagcctg 240
 cactcgggaa cagaaccgca tctgcaccgc taggcccggg acc 283

<210> 16
 <211> 31
 <212> DNA
 <213> Homo sapiens

<400> 16
 cgtgctgggt acccgcgag taccagccgg g 31

<210> 17
 <211> 298
 <212> DNA
 <213> Homo sapiens

<400> 17
 ggcccagccg gccatggccg ggagcacatg ccggctcaga gaatactatg accagacagc 60

tcagatgtgc tgcagcaagt gctcgccggg ccaacatgca aaagtcttct gtaccaagac 120
 ctcggaacacc gtgtgtgact cctgtgagga cagcacatac acccagctct ggaactgggt 180
 tcccagagtgc ttgagctgtg gctcccgtg tagctctgac caggtggaaa ctcaagcctg 240
 cactcgggaa cagaaccgca tctgcacctg caggcccggc tggtagtgcg cgggtacc 298

<210> 18
 <211> 29
 <212> DNA
 <213> Homo sapiens

<400> 18
 cgtgctgggt accctcctgc ttgctcage 29

<210> 19
 <211> 316
 <212> DNA
 <213> Homo sapiens

<400> 19
 ggcccagccg gccatggccg ggagcacatg ccggctcaga gaatactatg accagacagc 60
 tcagatgtgc tgcagcaagt gctcgccggg ccaacatgca aaagtcttct gtaccaagac 120
 ctcggaacacc gtgtgtgact cctgtgagga cagcacatac acccagctct ggaactgggt 180
 tcccagagtgc ttgagctgtg gctcccgtg tagctctgac caggtggaaa ctcaagcctg 240
 cactcgggaa cagaaccgca tctgcacctg caggcccggc tggtagtgcg cgctgagcaa 300
 gcaggagggg ggtacc 316

<210> 20
 <211> 44
 <212> DNA
 <213> Homo sapiens

<400> 20
 cgtgctgggt acctgcagcc agccgagccc cctcctgctt gctc 44

<210> 21
 <211> 331
 <212> DNA
 <213> Homo sapiens

<400> 21
 ggcccagccg gccatggccg ggagcacatg ccggctcaga gaatactatg accagacagc 60
 tcagatgtgc tgcagcaagt gctcgccggg ccaacatgca aaagtcttct gtaccaagac 120
 ctcggaacacc gtgtgtgact cctgtgagga cagcacatac acccagctct ggaactgggt 180
 tcccagagtgc ttgagctgtg gctcccgtg tagctctgac caggtggaaa ctcaagcctg 240
 cactcgggaa cagaaccgca tctgcacctg caggcccggc tggtagtgcg cgctgagcaa 300
 gcaggagggg gctcggctgg ctgcaggtac c 331

<210> 22

<211> 31
<212> DNA
<213> Homo sapiens

<400> 22
cgtgctgggt accggacgtg gacgtgcaga c 31

<210> 23
<211> 529
<212> DNA
<213> Homo sapiens

<400> 23
ggcccagccg gccatggccg ggagcacatg ccggctcaga gaatactatg accagacagc 60
tcagatgtgc tgcagcaagt gctcgccggg ccaacatgca aaagtcttct gtaccaagac 120
ctcggacacc gtgtgtgact cctgtgagga cagcacatac acccagctct ggaactgggt 180
tcccagagtgc ttgagctgtg gctcccgtg tagctctgac caggtggaaa ctcaagcctg 240
cactcgggaa cagaaccgca tctgcacctg caggcccggc tggtagtgcg cgctgagcaa 300
gcaggagggg tgccggctgt gcgcgccgt gcgcaagtgc cggccgggct tcggcgtggc 360
cagaccagga actgaaacat cagacgtggt gtgcaagccc tgtgccccgg ggacgttctc 420
caacacgact tcatccacgg atatttgag gccccaccag atctgtaacg tggtagccat 480
ccctgggaat gcaagcagg atgcagtctg cacgtccacg tccggtacc 529

<210> 24
<211> 44
<212> DNA
<213> Homo sapiens

<400> 24
gtgaccaggc ccagccggcc atggccgact cctgtgagga cagc 44

<210> 25
<211> 157
<212> DNA
<213> Homo sapiens

<400> 25
ggcccagccg gccatggccg actcctgtga ggacagcaca tacaccagc tctggaactg 60
ggttcccag tgcttgagct gtggctcccg ctgtagctct gaccaggtgg aaactcaagc 120
ctgcactcgg gaacagaacc gcatctgcac cggtagc 157

<210> 26
<211> 166
<212> DNA
<213> Homo sapiens

<400> 26
ggcccagccg gccatggccg actcctgtga ggacagcaca tacaccagc tctggaactg 60
ggttcccag tgcttgagct gtggctcccg ctgtagctct gaccaggtgg aaactcaagc 120
ctgcactcgg gaacagaacc gcatctgcac cgtaggccc ggtacc 166

<210> 27
 <211> 182
 <212> DNA
 <213> Homo sapiens

<400> 27
 ggcccagccg gccatggcct gactcctgtg aggacagcac atacacccag ctctggaact 60
 gggttcccgag gtgcttgagc tgtggctccc gctgtagctc tgaccagggtg gaaactcaag 120
 cctgcactcg ggaacagaac cgcactctgca cctgcaggcc cggctgggtac tgcgcgggta 180
 cc 182

<210> 28
 <211> 199
 <212> DNA
 <213> Homo sapiens

<400> 28
 ggcccagccg gccatggccg actcctgtga ggacagcaca tacacccagc tctggaactg 60
 ggttcccgag tgcttgagct gtggctcccg ctgtagctct gaccagggtg aaactcaagc 120
 ctgcactcgg gaacagaacc gcatctgcac ctgcaggccc ggctgggtact gcgcgctgag 180
 caagcaggag gggggtacc 199

<210> 29
 <211> 214
 <212> DNA
 <213> Homo sapiens

<400> 29
 ggcccagccg gccatggccg actcctgtga ggacagcaca tacacccagc tctggaactg 60
 ggttcccgag tgcttgagct gtggctcccg ctgtagctct gaccagggtg aaactcaagc 120
 ctgcactcgg gaacagaacc gcatctgcac ctgcaggccc ggctgggtact gcgcgctgag 180
 caagcaggag ggggctcggc tggctgcagg tacc 214

<210> 30
 <211> 412
 <212> DNA
 <213> Homo sapiens

<400> 30
 ggcccagccg gccatggccg actcctgtga ggacagcaca tacacccagc tctggaactg 60
 ggttcccgag tgcttgagct gtggctcccg ctgtagctct gaccagggtg aaactcaagc 120
 ctgcactcgg gaacagaacc gcatctgcac ctgcaggccc ggctgggtact gcgcgctgag 180
 caagcaggag ggggtgccggc tgtgcgcgcc gctgcgcaag tgccgcccgg gcttcggcgt 240
 ggccagacca ggaactgaaa catcagacgt ggtgtgcaag ccctgtgccc cggggacgtt 300
 ctccaacacg acttcatcca cggatatttg caggccccac cagatctgta acgtggtggc 360
 catccctggg aatgcaagca gggatgcagt ctgcacgtcc acgtccggta cc 412

<210> 31
 <211> 41
 <212> DNA
 <213> Homo sapiens

<400> 31
 gccagggatc catcgagggt aggggggagca catgccggct c 41

<210> 32
 <211> 278
 <212> DNA
 <213> Homo sapiens

<400> 32
 gccagggatc catcgagggt aggggggagca catgccggct cagagaatac tatgaccaga 60
 cagctcagat gtgctgcagc aagtgtctgc cgggcccaaca tgcaaaagtc ttctgtacca 120
 agacctcgga caccgtgtgt gactcctgtg aggacagcac atacaccag ctctggaact 180
 gggttcccgga gtgcttgagc tgtggctccc gctgtagctc tgaccagggtg gaaactcaag 240
 cctgcactcg ggaacagaac cgcactctgca ccgttacc 278

<210> 33
 <211> 287
 <212> DNA
 <213> Homo sapiens

<400> 33
 gccagggatc catcgagggt aggggggagca catgccggct cagagaatac tatgaccaga 60
 cagctcagat gtgctgcagc aagtgtctgc cgggcccaaca tgcaaaagtc ttctgtacca 120
 agacctcgga caccgtgtgt gactcctgtg aggacagcac atacaccag ctctggaact 180
 gggttcccgga gtgcttgagc tgtggctccc gctgtagctc tgaccagggtg gaaactcaag 240
 cctgcactcg ggaacagaac cgcactctgca ccgctaggcc cggtacc 287

<210> 34
 <211> 302
 <212> DNA
 <213> Homo sapiens

<400> 34
 gccagggatc catcgagggt aggggggagca catgccggct cagagaatac tatgaccaga 60
 cagctcagat gtgctgcagc aagtgtctgc cgggcccaaca tgcaaaagtc ttctgtacca 120
 agacctcgga caccgtgtgt gactcctgtg aggacagcac atacaccag ctctggaact 180
 gggttcccgga gtgcttgagc tgtggctccc gctgtagctc tgaccagggtg gaaactcaag 240
 cctgcactcg ggaacagaac cgcactctgca cctgcaggcc cggctggtac tgcgcgggta 300
 cc 302

<210> 35
 <211> 320
 <212> DNA
 <213> Homo sapiens

<400> 35
gccagggatc catcgagggt aggggggagca catgccggct cagagaatac tatgaccaga 60
cagctcagat gtgctgcagc aagtgtctgc cgggcccaaca tgcaaaagtc ttctgtacca 120
agacctcgga caccgtgtgt gactcctgtg aggacagcac atacaccag ctctggaact 180
gggttcccga gtgcttgagc tgtggctccc gctgtagctc tgaccaggtg gaaactcaag 240
cctgcactcg ggaacagaac cgcactctgca cctgcaggcc cggctggtac tgcgcgctga 300
gcaagcagga ggggggtacc 320

<210> 36
<211> 335
<212> DNA
<213> Homo sapiens

<400> 36
gccagggatc catcgagggt aggggggagca catgccggct cagagaatac tatgaccaga 60
cagctcagat gtgctgcagc aagtgtctgc cgggcccaaca tgcaaaagtc ttctgtacca 120
agacctcgga caccgtgtgt gactcctgtg aggacagcac atacaccag ctctggaact 180
gggttcccga gtgcttgagc tgtggctccc gctgtagctc tgaccaggtg gaaactcaag 240
cctgcactcg ggaacagaac cgcactctgca cctgcaggcc cggctggtac tgcgcgctga 300
gcaagcagga gggggctcgg ctggctgcag gtacc 335

<210> 37
<211> 533
<212> DNA
<213> Homo sapiens

<400> 37
gccagggatc catcgagggt aggggggagca catgccggct cagagaatac tatgaccaga 60
cagctcagat gtgctgcagc aagtgtctgc cgggcccaaca tgcaaaagtc ttctgtacca 120
agacctcgga caccgtgtgt gactcctgtg aggacagcac atacaccag ctctggaact 180
gggttcccga gtgcttgagc tgtggctccc gctgtagctc tgaccaggtg gaaactcaag 240
cctgcactcg ggaacagaac cgcactctgca cctgcaggcc cggctggtac tgcgcgctga 300
gcaagcagga ggggtgccgg ctgtgcgcgc cgctgcgcaa gtgccgcccg ggcttcggcg 360
tgccagagacc aggaactgaa acatcagacg tgggtgtgcaa gccctgtgcc ccggggacgt 420
tctccaacac gacttcatcc acggatattt gcaggcccca ccagatctgt aacgtggtgg 480
ccatccctgg gaatgcaagc agggatgcag tctgcacgtc cacgtccggt acc 533

<210> 38
<211> 44
<212> DNA
<213> Homo sapiens

<400> 38
gccagggatc catcgagggt aggggagcact cctgtgagga cagc 44

<210> 39
<211> 159
<212> DNA
<213> Homo sapiens

<400> 39
ggatccatcg agggtagggg cgactcctgt gaggacagca catacaccca gctctggaac 60
tgggttcccg agtgcttgag ctgtggctcc cgctgtagct ctgaccaggt ggaaactcaa 120
gcctgcactc gggaacagaa ccgcatctgc accggtacc 159

<210> 40
<211> 168
<212> DNA
<213> Homo sapiens

<400> 40
ggatccatcg agggtagggg cgactcctgt gaggacagca catacaccca gctctggaac 60
tgggttcccg agtgcttgag ctgtggctcc cgctgtagct ctgaccaggt ggaaactcaa 120
gcctgcactc gggaacagaa ccgcatctgc accgctaggc ccggtacc 168

<210> 41
<211> 183
<212> DNA
<213> Homo sapiens

<400> 41
ggatccatcg agggtagggg cgactcctgt gaggacagca catacaccca gctctggaac 60
tgggttcccg agtgcttgag ctgtggctcc cgctgtagct ctgaccaggt ggaaactcaa 120
gcctgcactc gggaacagaa ccgcatctgc acctgcaggc ccggctggta ctgcgcgggt 180
acc 183

<210> 42
<211> 201
<212> DNA
<213> Homo sapiens

<400> 42
ggatccatcg agggtagggg cgactcctgt gaggacagca catacaccca gctctggaac 60
tgggttcccg agtgcttgag ctgtggctcc cgctgtagct ctgaccaggt ggaaactcaa 120
gcctgcactc gggaacagaa ccgcatctgc acctgcaggc ccggctggta ctgcgcgctg 180
agcaagcagg aggggggtac c 201

<210> 43
<211> 216
<212> DNA
<213> Homo sapiens

<400> 43
ggatccatcg agggtagggg cgactcctgt gaggacagca catacaccca gctctggaac 60
tgggttcccg agtgcttgag ctgtggctcc cgctgtagct ctgaccaggt ggaaactcaa 120
gcctgcactc gggaacagaa ccgcatctgc acctgcaggc ccggctggta ctgcgcgctg 180

agcaagcagg aggggggctcg gctggctgca ggtacc

216

<210> 44
<211> 414
<212> DNA
<213> Homo sapiens

<400> 44
ggatccatcg agggtagggg cgactcctgt gaggacagca catacaccca gctctggaac 60
tgggttcccg agtgcttgag ctgtggctcc cgctgtagct ctgaccaggt ggaaactcaa 120
gcctgcactc gggaacagaa ccgcatctgc acctgcaggc ccggetggta ctgcgcgctg 180
agcaagcagg aggggtgccg gctgtgcgcg ccgctgcgca agtgccgccc gggcttcggc 240
gtggccagac caggaactga aacatcagac gtggtgtgca agccctgtgc cccggggacg 300
ttctccaaca cgacttcac caccgatatt tgcaggcccc accagatctg taacgtggtg 360
gccatccctg ggaatgcaag cagggatgca gtctgcacgt ccacgtccgg tacc 414

<210> 45
<211> 41
<212> DNA
<213> Homo sapiens

<400> 45
gccagagatc tatcgagggt agggaggtgc agctggtgga g 41

<210> 46
<211> 59
<212> DNA
<213> Homo sapiens

<400> 46
ctggtcggta ccggatccgc cgccaccact cgagacgggtg accagagtac cttggcccc 59

<210> 47
<211> 62
<212> DNA
<213> Homo sapiens

<400> 47
gcaggcggat ccgggggagg aggtagtggc ggtggtggat cagacatcca gatgaccag 60
tc 62

<210> 48
<211> 33
<212> DNA
<213> Homo sapiens

<400> 48
ccgagcggta cctttgattt ccaccttggc ccc 33

<210> 49
<211> 754
<212> DNA
<213> Homo sapiens

<400> 49
 agatctatcg agggtaggga ggtgcagctg gtggagtctg ggggaggctt ggtacagccc 60
 ggcagggtccc tgagactctc ctgtgcggcc tctggattca cctttgatga ttatgccatg 120
 cactgggtcc ggcaagctcc agggaagggc ctggaatggg tctcagctat cacttggaat 180
 agtggtcaca tagactatgc ggactctgtg gagggccgat tcaccatctc cagagacaac 240
 gccagaact ccctgtatct gcaaatgaac agtctgagag ctgaggatac ggccgtatat 300
 tactgtgcga aagtctcgta ccttagcacc gcgtcctccc ttgactattg gggccaaggt 360
 accctgggtca ccgtctcgag tgggtggcggc gggatccggg ggaggaggta gtggcgggtgg 420
 tggatcagac atccagatga ccagtcctcc atcctccctg tctgcatctg taggggacag 480
 agtcaccatc acttgctcggg caagtcaggg catcagaaat tacttagcct ggtatcagca 540
 aaaaccaggg aaagccccta agctcctgat ctatgctgca tccactttgc aatcaggggt 600
 cccatctcgg ttcagtggca gtggatctgg gacagatttc actctcacca tcagcagcct 660
 acagcctgaa gatgttgcaa cttattactg tcaaaggtat aaccgtgcac cgtatacttt 720
 tggccagggg accaaggtgg aaatcaaagg tacc 754

<210> 50
 <211> 48
 <212> DNA
 <213> Homo sapiens

<400> 50
 ccgagcggta ccagatccac cgcccccttt gatttccacc ttggtccc 48

<210> 51
 <211> 769
 <212> DNA
 <213> Homo sapiens

<400> 51
 agatctatcg agggtaggga ggtgcagctg gtggagtctg ggggaggctt ggtacagccc 60
 ggcagggtccc tgagactctc ctgtgcggcc tctggattca cctttgatga ttatgccatg 120
 cactgggtcc ggcaagctcc agggaagggc ctggaatggg tctcagctat cacttggaat 180
 agtggtcaca tagactatgc ggactctgtg gagggccgat tcaccatctc cagagacaac 240
 gccagaact ccctgtatct gcaaatgaac agtctgagag ctgaggatac ggccgtatat 300
 tactgtgcga aagtctcgta ccttagcacc gcgtcctccc ttgactattg gggccaaggt 360
 accctgggtca ccgtctcgag tgggtggcggc gggatccggg ggaggaggta gtggcgggtgg 420
 tggatcagac atccagatga ccagtcctcc atcctccctg tctgcatctg taggggacag 480
 agtcaccatc acttgctcggg caagtcaggg catcagaaat tacttagcct ggtatcagca 540
 aaaaccaggg aaagccccta agctcctgat ctatgctgca tccactttgc aatcaggggt 600
 cccatctcgg ttcagtggca gtggatctgg gacagatttc actctcacca tcagcagcct 660
 acagcctgaa gatgttgcaa cttattactg tcaaaggtat aaccgtgcac cgtatacttt 720

tggccagggg accaaggtgg aaatcaaagg gggcggtgga tctggtacc 769

<210> 52
 <211> 29
 <212> DNA
 <213> Homo sapiens

<400> 52
 gccagtgatc agaggtgcag ctggtggag 29

<210> 53
 <211> 33
 <212> DNA
 <213> Homo sapiens

<400> 53
 cctcgaagct tatttgattt ccaccttggt ccc 33

<210> 54
 <211> 743
 <212> DNA
 <213> Homo sapiens

<400> 54
 tgatcagagg tgcagctggt ggagtctggg ggaggcttgg tacagcccgg caggtccctg 60
 agactctcct gtgcggcctc tggattcacc tttgatgatt atgccatgca ctgggtccgg 120
 caagctccag ggaagggcct ggaatgggtc tcagctatca cttggaatag tggtcacata 180
 gactatgcgg actctgtgga gggccgattc accatctcca gagacaacgc caagaactcc 240
 ctgtatctgc aaatgaacag tctgagagct gaggatacgg ccgtatatta ctgtgcgaaa 300
 gtctcgtacc ttagcaccgc gtctccctt gactattggg gccaaaggtag cctgggtcacc 360
 gtctcgagtg gtggcgggcg gatccggggg aggaggtagt ggcgggtggtg gatcagacat 420
 ccagatgacc cagtctccat cctccctgtc tgcattctgta ggggacagag tcaccatcac 480
 ttgtcgggca agtcagggca tcagaaatta cttagcctgg tatcagcaaa aaccagggaa 540
 agcccctaag ctctgatct atgtgcac cactttgcaa tcaggggtcc catctcggtt 600
 cagtggcagt ggatctggga cagatttcac tctcaccatc agcagcctac agcctgaaga 660
 tgttgcaact tattactgtc aaaggtataa ccgtgcaccg tatacttttg gccaggggac 720
 caaggtggaa atcaaataag ctt 743

<210> 55
 <211> 44
 <212> DNA
 <213> Homo sapiens

<400> 55
 gccagtgatc aggaggtggc gggctctgagg tgcagctggt ggag 44

<210> 56
 <211> 758
 <212> DNA

<213> Homo sapiens

<400> 56

tgatcaggag gtggcgggtc tgaggtgcag ctggtggagt ctgggggagg cttggtacag	60
cccggcaggt ccctgagact ctctgtgcg gcctctggat tcacctttga tgattatgcc	120
atgcactggg tccggcaagc tccagggag ggcctggaat gggctctcagc tatcacttgg	180
aatagtggtc acatagacta tgcggactct gtggagggcc gattcaccat ctccagagac	240
aacgccaaga actccctgta tctgcaaag aacagtctga gagctgagga tacggccgta	300
tattactgtg cgaaagtctc gtaccttagc accgcgtcct cccttgacta ttggggccaa	360
ggtaccctgg tcaccgtctc gagtgggtggc ggcgggatcc gggggaggag gtagtggcgg	420
tggtggatca gacatccaga tgaccagtc tccatcctcc ctgtctgcat ctgtagggga	480
cagagtcacc atcacttgtc gggcaagtca gggcatcaga aattacttag cctggtatca	540
gcaaaaacca gggaaagccc ctaagctcct gatctatgct gcatccactt tgcaatcagg	600
ggtcccatct cggttcagtg gcagtggatc tgggacagat ttcactctca ccatcagcag	660
cctacagcct gaagatgttg caacttatta ctgtcaaagg tataaccgtg caccgtatac	720
ttttggccag gggaccaagg tggaaatcaa ataagctt	758

<210> 57

<211> 38

<212> DNA

<213> Homo sapiens

<400> 57

gccagagatc tatcgagggt aggatgagtg gcctgggc	38
---	----

<210> 58

<211> 18

<212> DNA

<213> Homo sapiens

<400> 58

catgcaggta cccagcag	18
---------------------	----

<210> 59

<211> 18

<212> DNA

<213> Homo sapiens

<400> 59

ctgctgggta cctgcatg	18
---------------------	----

<210> 60

<211> 32

<212> DNA

<213> Homo sapiens

<400> 60

cggcacggta ccgctcctga gcttgttctc ac	32
-------------------------------------	----

<210> 61

<211> 354
 <212> DNA
 <213> Homo sapiens

<400> 61
 agatctatcg agggtaggat gagtggcctg ggccggagca ggcgaggtgg ccggagccgt 60
 gtggaccagg aggagcgctt tccacagggc ctgtggacgg ggggtggctat gagatcctgc 120
 cccgaagagc agtactggga tctctgctg ggtacctgca tgtcctgcaa aaccatttgc 180
 aaccatcaga gccagcgcac ctgtgcagcc ttctgcaggt cactcagctg ccgcaaggag 240
 caaggcaagt tctatgacca tctcctgagg gactgcatca gctgtgcctc catctgtgga 300
 cagcacccta agcaatgtgc atacttctgt gagaacaagc tcaggagcgg tacc 354

<210> 62
 <211> 31
 <212> DNA
 <213> Homo sapiens

<400> 62
 cggcacggta ccaaggttca ctgggctcct g 31

<210> 63
 <211> 366
 <212> DNA
 <213> Homo sapiens

<400> 63
 agatctatcg agggtaggat gagtggcctg ggccggagca ggcgaggtgg ccggagccgt 60
 gtggaccagg aggagcgctt tccacagggc ctgtggacgg ggggtggctat gagatcctgc 120
 cccgaagagc agtactggga tctctgctg ggtacctgca tgtcctgcaa aaccatttgc 180
 aaccatcaga gccagcgcac ctgtgcagcc ttctgcaggt cactcagctg ccgcaaggag 240
 caaggcaagt tctatgacca tctcctgagg gactgcatca gctgtgcctc catctgtgga 300
 cagcacccta agcaatgtgc atacttctgt gagaacaagc tcaggagccc agtgaacctt 360
 ggtacc 366

<210> 64
 <211> 31
 <212> DNA
 <213> Homo sapiens

<400> 64
 cggcacggta cctccactcc gctgtctcct g 31

<210> 65
 <211> 396
 <212> DNA
 <213> Homo sapiens

<400> 65
 agatctatcg agggtaggat gagtggcctg ggccggagca ggcgaggtgg ccggagccgt 60
 gtggaccagg aggagcgctt tccacagggc ctgtggacgg ggggtggctat gagatcctgc 120

cccgaagagc agtactggga tcctctgctg ggtacctgca tgcctgcaa aaccatttgc 180
 aaccatcaga gccagcgcac ctgtgcagcc ttctgcaggt cactcagctg ccgcaaggag 240
 caaggcaagt tctatgacca tctcctgagg gactgcatca gctgtgcctc catctgtgga 300
 cagcacccta agcaatgtgc atacttctgt gagaacaagc tcaggagccc agtgaacctt 360
 ccaccagagc tcaggagaca gcggagtgga ggtacc 396

<210> 66
 <211> 36
 <212> DNA
 <213> Homo sapiens

<400> 66
 cggcacggta ccagggctca acagacttaa caaaag 36

<210> 67
 <211> 426
 <212> DNA
 <213> Homo sapiens

<400> 67
 agatctatcg agggtaggat gagtggcctg ggccggagca ggcgaggtgg ccggagccgt 60
 gtggaccagg aggagcgctt tccacagggc ctgtggacgg gggtagctat gagatcctgc 120
 cccgaagagc agtactggga tcctctgctg ggtacctgca tgcctgcaa aaccatttgc 180
 aaccatcaga gccagcgcac ctgtgcagcc ttctgcaggt cactcagctg ccgcaaggag 240
 caaggcaagt tctatgacca tctcctgagg gactgcatca gctgtgcctc catctgtgga 300
 cagcacccta agcaatgtgc atacttctgt gagaacaagc tcaggagccc agtgaacctt 360
 ccaccagagc tcaggagaca gcggagtgga gaagttgaaa acaattcaga caactcggga 420
 ggtacc 426

<210> 68
 <211> 31
 <212> DNA
 <213> Homo sapiens

<400> 68
 cggcacggta ccgctgtaga ccagggccac c 31

<210> 69
 <211> 519
 <212> DNA
 <213> Homo sapiens

<400> 69
 agatctatcg agggtaggat gagtggcctg ggccggagca ggcgaggtgg ccggagccgt 60
 gtggaccagg aggagcgctt tccacagggc ctgtggacgg gggtagctat gagatcctgc 120
 cccgaagagc agtactggga tcctctgctg ggtacctgca tgcctgcaa aaccatttgc 180
 aaccatcaga gccagcgcac ctgtgcagcc ttctgcaggt cactcagctg ccgcaaggag 240
 caaggcaagt tctatgacca tctcctgagg gactgcatca gctgtgcctc catctgtgga 300

cagcacccta agcaatgtgc atacttctgt gagaacaagc tcaggagccc agtgaacctt 360
ccaccagagc tcaggagaca gcggagtgga gaagttgaaa acaattcaga caactcgga 420
aggtaccaag gattggagca cagaggctca gaagcaagtc cagctctccc ggggctgaag 480
ctgagtgcag atcaggtggc cctggtctac agcgggtacc 519

<210> 70
<211> 41
<212> DNA
<213> Homo sapiens

<400> 70
ggccagggat ccatcgagg taggggggag caagcgccag g 41

<210> 71
<211> 31
<212> DNA
<213> Homo sapiens

<400> 71
cgggtgcggta cggggccaaa gcagccggaa g 31

<210> 72
<211> 186
<212> DNA
<213> Homo sapiens

<400> 72
ggatccatcg agggtagggg ggagcaagcg ccaggcaccg cccctgtct cgcgggcagc 60
tcttgagcgc cggacctgga caagtgcctg gactgcgcgt cttgcagggc gcgaccgcac 120
agcgacttct gcctgggctg cgctgcagca cctcctgcc ccttcgggt gctttggccc 180
ggtacc 186

<210> 73
<211> 41
<212> DNA
<213> Homo sapiens

<400> 73
ggccagggat ccatcgagg taggatgagg cgagggcccc g 41

<210> 74
<211> 28
<212> DNA
<213> Homo sapiens

<400> 74
cgggtgcggta ccgagcagcc cgggcagg 28

<210> 75
<211> 258
<212> DNA
<213> Homo sapiens

<400> 75

```

ggatccatcg agggtaggat gaggcgaggg ccccgagagcc tgcggggcag ggacgcgcca      60
gccccacgc cctgcgtccc ggccgagtgc ttcgacctgc tggtcgcga ctgcgtggcc      120
tgcggggtcc tgcgcacgcc gcggccgaaa cgggccgggg ccagcagccc tgcgccagg      180
acggcgctgc agccgcagga gtcggtgggc gcgggggccg gcgaggcggc gctgcccctg      240
cccgggctgc tcggtacc                                          258

```

```

<210> 76
<211> 235
<212> PRT
<213> Homo sapiens

```

```

<400> 76

```

```

Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser
1          5          10          15

```

```

Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys
          20          25          30

```

```

Ser Lys Cys Ser Pro Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr
          35          40          45

```

```

Ser Asp Thr Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu
          50          55          60

```

```

Trp Asn Trp Val Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser
65          70          75          80

```

```

Asp Gln Val Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys
          85          90          95

```

```

Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys
          100          105          110

```

```

Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala
          115          120          125

```

```

Arg Pro Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro
          130          135          140

```

```

Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His
145          150          155          160

```

```

Gln Ile Cys Asn Val Val Ala Ile Pro Gly Asn Ala Ser Met Asp Ala
          165          170          175

```

```

Val Cys Thr Ser Thr Ser Pro Thr Arg Ser Met Ala Pro Gly Ala Val
          180          185          190

```

```

His Leu Pro Gln Pro Val Ser Thr Arg Ser Gln His Thr Gln Pro Thr

```


195

200

205

Pro Glu Pro Ser Thr Ala Pro Ser Thr Ser Phe Leu Leu Pro Met Gly
 210 215 220

Pro Ser Pro Pro Ala Glu Gly Ser Thr Gly Asp
 225 230 235

<210> 77
 <211> 185
 <212> PRT
 <213> Homo sapiens

<400> 77

Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser
 1 5 10 15

Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys
 20 25 30

Ser Lys Cys Ser Pro Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr
 35 40 45

Ser Asp Thr Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu
 50 55 60

Trp Asn Trp Val Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser
 65 70 75 80

Asp Gln Val Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys
 85 90 95

Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys
 100 105 110

Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala
 115 120 125

Arg Pro Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro
 130 135 140

Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His
 145 150 155 160

Gln Ile Cys Asn Val Val Ala Ile Pro Gly Asn Ala Ser Met Asp Ala
 165 170 175

Val Cys Thr Ser Thr Ser Pro Thr Arg
 180 185

<210> 78

<211> 163
 <212> PRT
 <213> Homo sapiens

<400> 78

Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser
 1 5 10 15

Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys
 20 25 30

Ser Lys Cys Ser Pro Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr
 35 40 45

Ser Asp Thr Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu
 50 55 60

Trp Asn Trp Val Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser
 65 70 75 80

Asp Gln Val Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys
 85 90 95

Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys
 100 105 110

Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala
 115 120 125

Arg Pro Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys Ala Pro
 130 135 140

Gly Thr Phe Ser Asn Thr Thr Ser Ser Thr Asp Ile Cys Arg Pro His
 145 150 155 160

Gln Ile Cys

<210> 79
 <211> 142
 <212> PRT
 <213> Homo sapiens

<400> 79

Leu Pro Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro Gly Ser
 1 5 10 15

Thr Cys Arg Leu Arg Glu Tyr Tyr Asp Gln Thr Ala Gln Met Cys Cys
 20 25 30

Ser Lys Cys Ser Pro Gly Gln His Ala Lys Val Phe Cys Thr Lys Thr
 35 40 45

Ser Asp Thr Val Cys Asp Ser Cys Glu Asp Ser Thr Tyr Thr Gln Leu
50 55 60

Trp Asn Trp Val Pro Glu Cys Leu Ser Cys Gly Ser Arg Cys Ser Ser
65 70 75 80

Asp Gln Val Glu Thr Gln Ala Cys Thr Arg Glu Gln Asn Arg Ile Cys
85 90 95

Thr Cys Arg Pro Gly Trp Tyr Cys Ala Leu Ser Lys Gln Glu Gly Cys
100 105 110

Arg Leu Cys Ala Pro Leu Arg Lys Cys Arg Pro Gly Phe Gly Val Ala
115 120 125

Arg Pro Gly Thr Glu Thr Ser Asp Val Val Cys Lys Pro Cys
130 135 140

<210> 80
<211> 157
<212> PRT
<213> Homo sapiens

<400> 80

Val Arg Ser Ser Ser Arg Thr Pro Ser Asp Lys Pro Val Ala His Val
1 5 10 15

Val Ala Asn Pro Gln Ala Glu Gly Gln Leu Gln Trp Leu Asn Arg Arg
20 25 30

Ala Asn Ala Leu Leu Ala Asn Gly Val Glu Leu Arg Asp Asn Gln Leu
35 40 45

Val Val Pro Ser Glu Gly Leu Tyr Leu Ile Tyr Ser Gln Val Leu Phe
50 55 60

Lys Gly Gln Gly Cys Pro Ser Thr His Val Leu Leu Thr His Thr Ile
65 70 75 80

Ser Arg Ile Ala Val Ser Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala
85 90 95

Ile Lys Ser Pro Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala Lys
100 105 110

Pro Trp Tyr Glu Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu Lys
115 120 125

Gly Asp Arg Leu Ser Ala Glu Ile Asn Arg Pro Asp Tyr Leu Asp Phe
130 135 140

Ala Glu Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala Leu
 145 150 155

<210> 81
 <211> 51
 <212> PRT
 <213> Homo sapiens

<400> 81

Glu Pro Pro Thr Gln Lys Pro Lys Lys Leu Val Asn Ala Lys Lys Asp
 1 5 10 15

Val Val Asn Thr Lys Met Phe Glu Glu Leu Lys Ser Arg Leu Asp Thr
 20 25 30

Leu Ala Gln Glu Val Ala Leu Leu Lys Glu Gln Gln Ala Leu Gln Thr
 35 40 45

Val Cys Leu
 50

<210> 82
 <211> 39
 <212> DNA
 <213> Artificial

<220>
 <223> oligonucleotide primer

<400> 82
 gcgcacggat ccatggccca ggtggcattt acaccctac

39

<210> 83
 <211> 33
 <212> DNA
 <213> Artificial

<220>
 <223> oligonucleotide primer

<400> 83
 caccacggta ccgatctggt ggggcctgca aat

33

<210> 84
 <211> 738
 <212> DNA
 <213> Artificial

<220>
 <223> AD1D4-I162-tripB

<400> 84
 atgggatcca tggcccaggt ggcatttaca ccctacgcc cggagcccg gagcacatgc 60
 cggctcagag aatactatga ccagacagct cagatgtgct gcagcaaata ctcgccgggc 120
 caacatgcaa aagtcttctg taccaagacc tcggacaccg tgtgtgactc ctgtgaggac 180

```

agcacataca cccagctctg gaactggggt cccgagtgtg tgagctgtgg ctcccgtgtg      240
agctctgacc aggtggaaac tcaagcctgc actcgggaac agaaccgcat ctgcacctgc      300
aggcccggct ggtactgctg gctgagcaag caggaggggt gccggctgtg cgcgccgtgtg      360
cgcaagtgcc gcccgggctt cggcgtggcc agaccaggaa ctgaaacatc agacgtggtg      420
tgcaagccct gtgccccggg gacgttctcc aacacgactt catccacgga tatttgcagg      480
ccccaccaga tccgtaccga gccaccaacc cagaagccca agaagattgt aaatgccaaag      540
aaagatgttg tgaacacaaa gatgtttgag gagctcaaga gccgtctgga caccctggcc      600
caggaggtgg ccctgctgaa ggagcagcag gccctgcaga cggctctcct gaagggtcta      660
gaacaaaaac tcattctcaga agaggatctg aatagcgccg tcgaccatca tcatcatcat      720
cattgaaagc tgaattcc                                     738

```

```

<210> 85
<211> 51
<212> DNA
<213> Artificial

```

```

<220>
<223> oligonucleotide primer

```

```

<400> 85
caccacggta ccggaggaac cggaggacgt ggacgtgcag actgcatcca t      51

```

```

<210> 86
<211> 810
<212> DNA
<213> Artificial

```

```

<220>
<223> AD1D4-GSS-tripB

```

```

<400> 86
atgggatcca tggcccaggt ggcatttaca ccctacgcc cggagcccgg gagcacatgc      60
cggctcagag aatactatga ccagacagct cagatgtgct gcagcaaattg ctgcgccgggc      120
caacatgcaa aagtcttctg taccaagacc tccgacaccg tgtgtgactc ctgtgaggac      180
agcacataca cccagctctg gaactggggt cccgagtgtg tgagctgtgg ctcccgtgtg      240
agctctgacc aggtggaaac tcaagcctgc actcgggaac agaaccgcat ctgcacctgc      300
aggcccggct ggtactgctg gctgagcaag caggaggggt gccggctgtg cgcgccgtgtg      360
cgcaagtgcc gcccgggctt cggcgtggcc agaccaggaa ctgaaacatc agacgtggtg      420
tgcaagccct gtgccccggg gacgttctcc aacacgactt catccacgga tatttgcagg      480
ccccaccaga tctgtaacgt ggtggccatc cctgggaatg caagcatgga tgcagtctgc      540
acgtccacgt cctccggttc ctccgggtacc gagccacca cccagaagcc caagaagatt      600
gtaaatgcca agaaagatgt tgtgaacaca aagatgtttg aggagctcaa gagccgtctg      660
gacaccctgg cccaggaggt ggccctgctg aaggagcagc aggcctgca gacgggtctcc      720

```

ctgaaggggtc tagaacaaaa actcatctca gaagaggatc tgaatagcgc cgtcgaccat 780
catcatcatc atcattgaaa gctgaattcc 810

<210> 87
<211> 39
<212> DNA
<213> Artificial

<220>
<223> oligonucleotide primer

<400> 87
agatttggtc cgcgcgccag tgctcccttc agctggggg 39

<210> 88
<211> 957
<212> DNA
<213> Artificial

<220>
<223> AD1D4-D235-tripB

<400> 88
atgggatcca tggcccaggt ggcatttaca ccctacgccc cggagcccgg gagcacatgc 60
cggctcagag aatactatga ccagacagct cagatgtgct gcagcaaagc ctcgccgggc 120
caacatgcaa aagtcttctg taccaagacc tcggacaccg tgtgtgactc ctgtgaggac 180
agcacatata ccagctctg gaactgggtt cccgagtgtc tgagctgtgg ctcccgtgt 240
agctctgacc aggtggaaac tcaagcctgc actcgggaac agaaccgcat ctgcacctgc 300
aggcccggct ggtactgctc gctgagcaag caggaggggt gccggctgtg cgcgccgctg 360
cgcaagtgcc gcccgggctt cggcgtggcc agaccaggaa ctgaaacatc agacgtggtg 420
tgcaagccct gtgccccggg gacgttctcc aacacgactt catccacgga tatttgcagg 480
ccccaccaga tctgtaacgt ggtggccatc cctgggaatg caagcatgga tgcagtctgc 540
acgtccacgt ccccccaccg gagtatggcc ccaggggagc tacacttacc ccagccagtg 600
tccacacgat cccaacacac gcagccaact ccagaacca gcaactgtcc aagcacctcc 660
ttctgtctcc caatgggccc cagcccccca gctgaaggga gcaactggcg cggtagccag 720
ccaccaaccc agaagcccaa gaagattgta aatgccaaag aagatgttgt gaacacaaag 780
atgtttgagg agctcaagag ccgtctggac accctggccc aggaggtggc cctgctgaag 840
gagcagcagg ccctgcagac ggtctccctg aagggtctag aacaaaaact catctcagaa 900
gaggatctga atagcgccgt cgaccatcat catcatcatc attgaaagct gaattcc 957

<210> 89
<211> 711
<212> DNA
<213> Artificial

<220>
<223> AD1D4-I162-I10-TripB

<400> 89
atgggatcca tggcccaggt ggcatttaca ccctacgccc cggagcccgg gagcacatgc 60
cggctcagag aatactatga ccagacagct cagatgtgct gcagcaaatg ctgccggggc 120
caacatgcaa aagtcttctg taccaagacc tcggacaccg tgtgtgactc ctgtgaggac 180
agcacatata ccagctctg gaactgggtt cccgagtgtc tgagctgtgg ctcccgtgt 240
agctctgacc aggtggaaac tcaagcctgc actcgggaac agaaccgcat ctgcacctgc 300
aggcccggct ggtactgctg gctgagcaag caggaggggt gccggctgtg cgcgccgctg 360
cgcaagtgcc gcccgggctt cggcgtggcc agaccaggaa ctgaaacatc agacgtggtg 420
tgcaagccct gtgccccggg gacgttctcc aacacgactt catccacgga tatttgcagg 480
ccccaccaga tcggtaccat tgtaaatacc aagaaagatg ttgtgaacac aaagatgttt 540
gaggagctca agagccgtct ggacaccctg gcccaggagg tggccctgct gaaggagcag 600
caggccctgc agacggtctc cctgaagggt ctagaacaaa aactcatctc agaagaggat 660
ctgaatagcg ccgtcgacca tcatcatcat catcattgaa agctgaattc c 711

<210> 90
<211> 711
<212> DNA
<213> Artificial

<220>
<223> AD1D4-GSS-I10-tripB

<400> 90
atgggatcca tggcccaggt ggcatttaca ccctacgccc cggagcccgg gagcacatgc 60
cggctcagag aatactatga ccagacagct cagatgtgct gcagcaaatg ctgccggggc 120
caacatgcaa aagtcttctg taccaagacc tcggacaccg tgtgtgactc ctgtgaggac 180
agcacatata ccagctctg gaactgggtt cccgagtgtc tgagctgtgg ctcccgtgt 240
agctctgacc aggtggaaac tcaagcctgc actcgggaac agaaccgcat ctgcacctgc 300
aggcccggct ggtactgctg gctgagcaag caggaggggt gccggctgtg cgcgccgctg 360
cgcaagtgcc gcccgggctt cggcgtggcc agaccaggaa ctgaaacatc agacgtggtg 420
tgcaagccct gtgccccggg gacgttctcc aacacgactt catccacgga tatttgcagg 480
ccccaccaga tcggtaccat tgtaaatacc aagaaagatg ttgtgaacac aaagatgttt 540
gaggagctca agagccgtct ggacaccctg gcccaggagg tggccctgct gaaggagcag 600
caggccctgc agacggtctc cctgaagggt ctagaacaaa aactcatctc agaagaggat 660
ctgaatagcg ccgtcgacca tcatcatcat catcattgaa agctgaattc c 711

<210> 91
<211> 930
<212> DNA
<213> Artificial

<220>
<223> AD1D4-D235-I10-tripB

<400> 91
 atgggatcca tggcccaggt ggcattttaca ccctacgccc cggagcccgg gagcacatgc 60
 cggctcagag aatactatga ccagacagct cagatgtgct gcagcaaagt ctcgccgggc 120
 caacatgcaa aagtcttctg taccaagacc tcggacaccg tgtgtgactc ctgtgaggac 180
 agcacatata ccagctctg gaactgggtt cccgagtgtc tgagctgtgg ctcccgtgt 240
 agctctgacc aggtggaaac tcaagcctgc actcgggaac agaaccgcat ctgcacctgc 300
 agggccggct ggtactgctg gctgagcaag caggaggggt gccggctgtg cgcgccgctg 360
 cgcaagtgcc gcccgggctt cggcgtggcc agaccaggaa ctgaaacatc agacgtggtg 420
 tgcaagccct gtgccccggg gacgtttctc aacacgactt catccacgga tatttgagg 480
 ccccaccaga tctgtaacgt ggtggccatc cctgggaatg caagcatgga tgcagtctgc 540
 acgtccacgt cccccaccg gagtatggcc ccaggggcag tacacttacc ccagccagt 600
 tccacacgat cccaacacac gcagccaact ccagaaccca gactgctcc aagcacctcc 660
 ttctgtctcc caatgggccc cagcccccca gctgaaggga gactggcga cggtaccatt 720
 gtaaattgcca agaaagatgt tgtgaacaca aagatgtttg aggagctcaa gagccgtctg 780
 gacaccctgg ccagagggt ggccctgctg aaggagcagc aggcctgca gacggtctcc 840
 ctgaagggtc tagaacaaaa actcatctca gaagaggatc tgaatagcgc cgtcgaccat 900
 catcatcatc atcattgaaa gctgaattcc 930

<210> 92
 <211> 31
 <212> DNA
 <213> Artificial

<220>
 <223> pKpnI-V17

<400> 92
 gacggtaccg ttgtgaacac aaagatgttt g 31

<210> 93
 <211> 35
 <212> DNA
 <213> Artificial

<220>
 <223> pBAD6H

<400> 93
 ggctcggaat tcaatgatga tgatgatgat ggtcg 35

<210> 94
 <211> 762
 <212> DNA
 <213> Artificial

<220>
 <223> AD1D4-GSS-V17-tripB

<400> 94
 atgggatcca tggcccaggt ggcattttaca ccctacgccc cggagcccgg gagcacatgc 60
 cggctcagag aatactatga ccagacagct cagatgtgct gcagcaaagtg ctccgcccggc 120
 caacatgcaa aagtcttctg taccaagacc tcggacaccg tgtgtgactc ctgtgaggac 180
 agcacatata ccagctctg gaactgggtt cccgagtgtg tgagctgtgg ctcccgtgtg 240
 agctctgacc aggtggaaac tcaagcctgc actcgggaac agaaccgcat ctgcacctgc 300
 agggccggct ggtactgccc gctgagcaag caggaggggt gccggctgtg cgcgccgctg 360
 cgcaagtgcc gcccgggctt cggcgtggcc agaccaggaa ctgaaacatc agacgtgggtg 420
 tgcaagccct gtgccccggg gacgttctcc aacacgactt catccacgga tatttgagg 480
 ccccaccaga tctgtaacgt ggtggccatc cctgggaatg caagcatgga tgcagtctgc 540
 acgtccacgt cctccggttc ctccggtacc gttgtgaaca caaagatgtt tgaggagctc 600
 aagagccgtc tggacaccct ggcccaggag gtggccctgc tgaaggagca gcaggccctg 660
 cagacggtct ccctgaaggg tctagaacaa aaactcatct cagaagagga tctgaatagc 720
 gccgtcgacc atcatcatca tcatcattga aagctgaatt cc 762

<210> 95
 <211> 909
 <212> DNA
 <213> Artificial

<220>
 <223> AD1D4-D235-V17-tripB

<400> 95
 atgggatcca tggcccaggt ggcattttaca ccctacgccc cggagcccgg gagcacatgc 60
 cggctcagag aatactatga ccagacagct cagatgtgct gcagcaaagtg ctccgcccggc 120
 caacatgcaa aagtcttctg taccaagacc tcggacaccg tgtgtgactc ctgtgaggac 180
 agcacatata ccagctctg gaactgggtt cccgagtgtg tgagctgtgg ctcccgtgtg 240
 agctctgacc aggtggaaac tcaagcctgc actcgggaac agaaccgcat ctgcacctgc 300
 agggccggct ggtactgccc gctgagcaag caggaggggt gccggctgtg cgcgccgctg 360
 cgcaagtgcc gcccgggctt cggcgtggcc agaccaggaa ctgaaacatc agacgtgggtg 420
 tgcaagccct gtgccccggg gacgttctcc aacacgactt catccacgga tatttgagg 480
 ccccaccaga tctgtaacgt ggtggccatc cctgggaatg caagcatgga tgcagtctgc 540
 acgtccacgt cccccaccg gagtatggcc ccaggggagc tacacttacc ccagccagtg 600
 tccacacgat cccaacacac gcagccaact ccagaacca gactgctcc aagcacctcc 660
 ttctgtctcc caatgggccc cagcccccca gctgaaggga gactggcga cggtagcgtt 720
 gtgaacacaa agatgtttga ggagctcaag agcgtctgtg acaccctggc ccaggaggtg 780
 gccctgctga aggagcagca ggccctgcag acggtctccc tgaagggtct agaacaaaaa 840
 ctcatctcag aagaggatct gaatagcgcc gtcgaccatc atcatcatca tcattgaaa 900

ctgaattcc

909

<210> 96
 <211> 181
 <212> PRT
 <213> Homo sapiens

<400> 96

Glu Pro Pro Thr Gln Lys Pro Lys Lys Ile Val Asn Ala Lys Lys Asp
 1 5 10 15

Val Val Asn Thr Lys Met Phe Glu Glu Leu Lys Ser Arg Leu Asp Thr
 20 25 30

Leu Ala Gln Glu Val Ala Leu Leu Lys Glu Gln Gln Ala Leu Gln Thr
 35 40 45

Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys Phe Leu Ala Phe
 50 55 60

Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp Cys Ile Ser Arg
 65 70 75 80

Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu Asn Asp Ala Leu
 85 90 95

Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala Glu Ile Trp Leu
 100 105 110

Gly Leu Asn Asp Met Ala Ala Glu Gly Thr Trp Val Asp Met Thr Gly
 115 120 125

Ala Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile Thr Ala Gln Pro
 130 135 140

Asp Gly Gly Lys Thr Glu Asn Cys Ala Val Leu Ser Gly Ala Ala Asn
 145 150 155 160

Gly Lys Trp Phe Asp Lys Arg Cys Arg Asp Gln Leu Pro Tyr Ile Cys
 165 170 175

Gln Phe Gly Ile Val
 180

<210> 97
 <211> 137
 <212> PRT
 <213> Homo sapiens

<400> 97

Ala Leu Gln Thr Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys
 1 5 10 15

Phe Leu Ala Phe Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp
 20 25 30

Cys Ile Ser Arg Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu
 35 40 45

Asn Asp Ala Leu Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala
 50 55 60

Glu Ile Trp Leu Gly Leu Asn Asp Met Ala Ala Glu Gly Thr Trp Val
 65 70 75 80

Asp Met Thr Gly Ala Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile
 85 90 95

Thr Ala Gln Pro Asp Gly Gly Lys Thr Glu Asn Cys Ala Val Leu Ser
 100 105 110

Gly Ala Ala Asn Gly Lys Trp Phe Asp Lys Arg Cys Arg Asp Gln Leu
 115 120 125

Pro Tyr Ile Cys Gln Phe Gly Ile Val
 130 135

<210> 98
 <211> 102
 <212> DNA
 <213> Artificial

<220>
 <223> TN-lib3-tprev

<220>
 <221> misc_feature
 <222> (22)..(23)
 <223> randomised

<220>
 <221> misc_feature
 <222> (25)..(26)
 <223> randomised

<220>
 <221> misc_feature
 <222> (28)..(29)
 <223> randomised

<220>
 <221> misc_feature
 <222> (31)..(32)
 <223> randomised

<220>

<221> misc_feature
<222> (34)..(35)
<223> randomised

<220>
<221> misc_feature
<222> (37)..(38)
<223> randomised

<220>
<221> misc_feature
<222> (40)..(41)
<223> randomised

<400> 98
gagatctggc tgggcctcaa cnsnnsnns nnsnnsnns nstgggtgga catgaccggt 60
accgcatcg cctacaagaa ctgggagact gagatcaccg cg 102

<210> 99
<211> 94
<212> DNA
<213> Artificial

<220>
<223> TN-lib2-tprev

<220>
<221> misc_feature
<222> (17)..(17)
<223> randomised

<220>
<221> misc_feature
<222> (18)..(18)
<223> randomised

<220>
<221> misc_feature
<222> (20)..(21)
<223> randomised

<220>
<221> misc_feature
<222> (23)..(24)
<223> randomised

<220>
<221> misc_feature
<222> (29)..(29)
<223> randomised

<220>
<221> misc_feature
<222> (30)..(30)
<223> randomised

<220>

<221> misc_feature

<222> (32)..(33)

<223> randomised

<400> 99

gctgggcctc aacgacnnsn nsnnsgagnn snnstgggtg gacatgaccg gtacccgcat 60

cgctacaag aactgggaga ctgagatcac cgcg 94

<210> 100

<211> 108

<212> DNA

<213> Artificial

<220>

<223> TN-lib3-tpfo

<220>

<221> misc_feature

<222> (63)..(64)

<223> randomised

<220>

<221> misc_feature

<222> (66)..(67)

<223> randomised

<220>

<221> misc_feature

<222> (69)..(70)

<223> randomised

<220>

<221> misc_feature

<222> (72)..(73)

<223> randomised

<220>

<221> misc_feature

<222> (75)..(76)

<223> randomised

<220>

<221> misc_feature

<222> (78)..(79)

<223> randomised

<400> 100

cgcggcagcg cttgtcgaac cacttgccgt tggccgcgcc tgacaggacc gcgcagttct 60

csnnsnnsnn snnsnnsna tcgggttgcg cggatgatctc agtctccc 108

<210> 101

<211> 102

<212> DNA

<213> Artificial

<220>
 <223> TN-lib2-tpfo

<220>
 <221> misc_feature
 <222> (63)..(64)
 <223> randomised

<220>
 <221> misc_feature
 <222> (66)..(67)
 <223> randomised

<220>
 <221> misc_feature
 <222> (69)..(70)
 <223> randomised

<220>
 <221> misc_feature
 <222> (72)..(73)
 <223> randomised

<400> 101
 cgcggcagcg cttgtcgaac cacttgccgt tggccgcgcc tgacaggacc gcgcagttct 60
 csnnnsnnnn snnatcgggt tgcgcggtga tctcagttct cc 102

<210> 102
 <211> 137
 <212> PRT
 <213> Artificial

<220>
 <223> TN3-2

<400> 102

Ala Leu Gln Thr Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys
 1 5 10 15

Phe Leu Ala Phe Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp
 20 25 30

Cys Ile Ser Arg Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu
 35 40 45

Asn Asp Ala Leu Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala
 50 55 60

Glu Ile Trp Leu Gly Leu Asn Lys Val Arg Ser Arg Tyr Phe Trp Met
 65 70 75 80

Asp Met Thr Gly Thr Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile
 85 90 95

Thr Ala Gln Pro Asp Pro Arg His Thr Glu Asn Cys Ala Val Leu Ser
 100 105 110

Gly Ala Ala Asn Gly Lys Trp Phe Asp Lys Arg Cys Arg Asp Gln Leu
 115 120 125

Pro Tyr Ile Cys Gln Phe Gly Ile Val
 130 135

<210> 103
 <211> 137
 <212> PRT
 <213> Artificial

<220>
 <223> TN3-2-B

<400> 103

Ala Leu Gln Thr Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys
 1 5 10 15

Phe Leu Ala Phe Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp
 20 25 30

Cys Ile Ser Arg Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu
 35 40 45

Asn Asp Ala Leu Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala
 50 55 60

Glu Ile Trp Leu Gly Leu Asn Lys Val Arg Ser Arg Tyr Phe Trp Met
 65 70 75 80

Asp Met Thr Gly Thr Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile
 85 90 95

Thr Ala Gln Pro Asp Pro Thr Asn Asn Glu Asn Cys Ala Val Leu Ser
 100 105 110

Gly Ala Ala Asn Gly Lys Trp Phe Gly Lys Arg Cys Arg Asp Gln Leu
 115 120 125

Pro Tyr Ile Cys Gln Phe Gly Ile Val
 130 135

<210> 104
 <211> 137
 <212> PRT
 <213> Artificial

<220>
 <223> TN3-2-C

<400> 104

Ala Leu Gln Thr Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys
1 5 10 15

Phe Leu Ala Phe Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp
20 25 30

Cys Ile Ser Arg Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu
35 40 45

Asn Asp Ala Leu Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala
50 55 60

Glu Ile Trp Leu Gly Leu Asn Lys Val Arg Ser Arg Tyr Phe Trp Val
65 70 75 80

Asp Met Thr Gly Thr Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile
85 90 95

Thr Ala Gln Pro Asp Pro Thr Asn Arg Glu Asn Cys Ala Val Leu Ser
100 105 110

Gly Ala Ala Asn Gly Lys Trp Phe Asp Lys Arg Cys Arg Asp Gln Leu
115 120 125

Pro Tyr Ile Cys Gln Phe Gly Ile Val
130 135

<210> 105
<211> 137
<212> PRT
<213> Artificial

<220>
<223> TN3-2-D

<400> 105

Ala Leu Gln Thr Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys
1 5 10 15

Phe Leu Ala Phe Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp
20 25 30

Cys Ile Ser Arg Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu
35 40 45

Asn Asp Ala Leu Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala
50 55 60

Glu Ile Trp Leu Gly Leu Asn Lys Val Arg Ser Arg Tyr Phe Trp Ile
65 70 75 80

Asp Met Thr Gly Thr Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile
85 90 95

Thr Ala Gln Pro Asp Pro Asn Asn Arg Glu Asn Cys Ala Val Leu Ser
100 105 110

Gly Ala Ala Asn Gly Lys Trp Phe Gly Lys Arg Cys Arg Asp Gln Leu
115 120 125

Pro Tyr Ile Cys Gln Phe Gly Ile Val
130 135

<210> 106
<211> 181
<212> PRT
<213> Artificial

<220>
<223> TN-2-B

<400> 106

Glu Pro Pro Thr Gln Lys Pro Lys Lys Ile Val Asn Ala Lys Lys Asp
1 5 10 15

Val Val Asn Thr Lys Met Phe Glu Glu Leu Lys Ser Arg Leu Asp Thr
20 25 30

Leu Ala Gln Glu Val Ala Leu Leu Lys Glu Gln Gln Ala Leu Gln Thr
35 40 45

Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys Phe Leu Ala Phe
50 55 60

Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp Cys Ile Ser Arg
65 70 75 80

Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu Asn Asp Ala Leu
85 90 95

Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala Glu Ile Trp Leu
100 105 110

Gly Leu Asn Lys Val Arg Ser Arg Tyr Phe Trp Met Asp Met Thr Gly
115 120 125

Thr Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile Thr Ala Gln Pro
130 135 140

Asp Pro Thr Asn Asn Glu Asn Cys Ala Val Leu Ser Gly Ala Ala Asn
145 150 155 160

Gly Lys Trp Phe Gly Lys Arg Cys Arg Asp Gln Leu Pro Tyr Ile Cys

165

170

175

Gln Phe Gly Ile Val
180

<210> 107
<211> 181
<212> PRT
<213> Artificial

<220>
<223> TN-2-D

<400> 107

Glu Pro Pro Thr Gln Lys Pro Lys Lys Ile Val Asn Ala Lys Lys Asp
1 5 10 15

Val Val Asn Thr Lys Met Phe Glu Glu Leu Lys Ser Arg Leu Asp Thr
20 25 30

Leu Ala Gln Glu Val Ala Leu Leu Lys Glu Gln Gln Ala Leu Gln Thr
35 40 45

Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys Phe Leu Ala Phe
50 55 60

Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp Cys Ile Ser Arg
65 70 75 80

Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu Asn Asp Ala Leu
85 90 95

Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala Glu Ile Trp Leu
100 105 110

Gly Leu Asn Lys Val Arg Ser Arg Tyr Phe Trp Ile Asp Met Thr Gly
115 120 125

Thr Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile Thr Ala Gln Pro
130 135 140

Asp Pro Asn Asn Arg Glu Asn Cys Ala Val Leu Ser Gly Ala Ala Asn
145 150 155 160

Gly Lys Trp Phe Gly Lys Arg Cys Arg Asp Gln Leu Pro Tyr Ile Cys
165 170 175

Gln Phe Gly Ile Val
180

<210> 108
<211> 181

<212> PRT
<213> Artificial

<220>
<223> TN-2-C

<400> 108

Glu Pro Pro Thr Gln Lys Pro Lys Lys Ile Val Asn Ala Lys Lys Asp
1 5 10 15

Val Val Asn Thr Lys Met Phe Glu Glu Leu Lys Ser Arg Leu Asp Thr
20 25 30

Leu Ala Gln Glu Val Ala Leu Leu Lys Glu Gln Gln Ala Leu Gln Thr
35 40 45

Val Cys Leu Lys Gly Thr Lys Val His Met Lys Cys Phe Leu Ala Phe
50 55 60

Thr Gln Thr Lys Thr Phe His Glu Ala Ser Glu Asp Cys Ile Ser Arg
65 70 75 80

Gly Gly Thr Leu Ser Thr Pro Gln Thr Gly Ser Glu Asn Asp Ala Leu
85 90 95

Tyr Glu Tyr Leu Arg Gln Ser Val Gly Asn Glu Ala Glu Ile Trp Leu
100 105 110

Gly Leu Asn Lys Val Arg Ser Arg Tyr Phe Trp Val Asp Met Thr Gly
115 120 125

Thr Arg Ile Ala Tyr Lys Asn Trp Glu Thr Glu Ile Thr Ala Gln Pro
130 135 140

Asp Pro Thr Asn Arg Glu Asn Cys Ala Val Leu Ser Gly Ala Ala Asn
145 150 155 160

Gly Lys Trp Phe Asp Lys Arg Cys Arg Asp Gln Leu Pro Tyr Ile Cys
165 170 175

Gln Phe Gly Ile Val
180

<210> 109
<211> 256
<212> PRT
<213> Artificial

<220>
<223> AD1D4-GSS-I10

<400> 109

Met Gly Ser Met Ala Gln Val Ala Phe Thr Pro Tyr Ala Pro Glu Pro

Page 37

(12) INTERNATIONAL PUBLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
13 May 2004 (13.05.2004)

PCT

(10) International Publication Number
WO 2004/039841 A3

(51) International Patent Classification⁷: **C07K 14/52**,
C12N 5/10, A61K 38/19, C07K 14/525, C12N 15/10,
G01N 33/68, C07K 14/725, C12N 5/28, A61P 29/00

[DK/DK]; Strandvejen 4, DK-8410 Rønne (DK). **ANDERSEN**, Mikkel, Holmen [DK/DK]; Skt. Pauls Gade 68
1. Sal, DK-8000 Århus C (DK). **OTTOW**, Helle, Krogh
[DK/DK]; Langballevej 74, DK-8320 Mårslet (DK).

(21) International Application Number:
PCT/DK2003/000735

(74) Common Representative: **BOREAN PHARMA A/S**;
Gustav Wieds Vej 10, DK-8000 Aarhus C (DK).

(22) International Filing Date: 29 October 2003 (29.10.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2002 01634 29 October 2002 (29.10.2002) DK
60/421,807 29 October 2002 (29.10.2002) US

(71) Applicant (*for all designated States except US*): **BOREAN PHARMA A/S** [DK/DK]; Gustav Wieds Vej 10, DK-8000 Aarhus C (DK).


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HOLTET, Thor, Las**

[Continued on next page]

(54) Title: TRIMERIC BINDING PROTEINS FOR TRIMERIC CYTOKINES



(57) Abstract: The present invention pertains to the provision of trimeric binding units which bind to trimeric cytokines. In particular there is provided a trimeric polypeptide comprising a trimerising domain and three monomers with binding members capable of binding a trimeric cytokine. Preferably, the trimeric binding units bind in a manner such that upon binding, all receptor binding sites of the trimeric cytokine are substantially blocked, and hence the potential biological activity of the trimeric cytokine is suppressed. In one aspect the invention relates to trimeric binders capable of binding to trimeric cytokines of the Tumor necrosis factor ligand superfamily, such as TNF, TRAIL, RANKL, TWEAK, APRIL and BAFF.



Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(88) Date of publication of the international search report:

10 September 2004

INTERNATIONAL SEARCH REPORT

Int. Application No
PCT/EP 03/00735

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/52 C12N5/10 A61K38/19 C07K14/525 C12N15/10
G01N33/68 C07K14/725 C12N5/28 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, SEQUENCE SEARCH, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 03/060072 A (IMMUNEX CORP ;REDDY PRANHITHA (US)) 24 July 2003 (2003-07-24) claims 1-21	1-6
P,X	WO 03/033720 A (DESJARLAIS JOHN R ;ZALEVSKY JONATHAN (US); FILIKOV ANTON (US); MUC) 24 April 2003 (2003-04-24) claims 1-71	1-6
P,X	WO 03/057856 A (DESJARLAIS JOHN R ;TANSEY MALU LOURDES G (US); XENCOR (US); DAHIYA) 17 July 2003 (2003-07-17) claims 1-44	1-6
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 April 2004

Date of mailing of the international search report

26 JUL 2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

fernando farieta

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/DK 03/00735

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BODMER JEAN-LUC ET AL: "The molecular architecture of the TNF superfamily." TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND JAN 2002, vol. 27, no. 1, January 2002 (2002-01), pages 19-26, XP002276709 ISSN: 0968-0004 figure 1 ---	1-6
X	WO 01/64889 A (XENCOR) 7 September 2001 (2001-09-07) claims 1-13; figure 1 ---	1-6
A	WO 98/05783 A (CHICHEPORTICHE YVES ;FACULTY OF MEDICINE OF THE UNI (CH); BIOGEN I) 12 February 1998 (1998-02-12) claims 1-35 ---	1-6
A	WO 99/11791 A (UNIV WASHINGTON) 11 March 1999 (1999-03-11) claim 38 ---	1-6
P,A	US 2003/119149 A1 (REDDY PRANHITHA) 26 June 2003 (2003-06-26) claims 1-21 ---	1-6
P,A	US 2003/053984 A1 (HOLLER NILS ET AL) 20 March 2003 (2003-03-20) claims 1-28 ---	1-6
E	WO 2004/012673 A (Kuai JUN ;LIN LIH-LING (US); WYETH CORP (US); NICKBARG ELLIOTT (US) 12 February 2004 (2004-02-12) claims 1-57 ---	1-6
A	KORNBLUTH RICHARD S: "An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection." JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH. UNITED STATES OCT 2002, vol. 11, no. 5, October 2002 (2002-10), pages 787-801, XP002276710 ISSN: 1525-8165 Table 1 ---	1-6
A	IDRISS H T ET AL: "TNF alpha and the TNF receptor superfamily: structure-function relationship(s)." MICROSCOPY RESEARCH AND TECHNIQUE. UNITED STATES 1 AUG 2000, vol. 50, no. 3, 1 August 2000 (2000-08-01), pages 184-195, XP002276711 ISSN: 1059-910X Table 2 -----	1-6

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 03/00735

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **24-25**
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: **22,31 and part of 1-3**
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
2-3 and part of claim 1

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 24-25

Claims 24-25 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practised on the human or animal body (PCT Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

Continuation of Box I.2

Claims Nos.: 22,31 and part of 1-3

In view of the large number and also the wording "specific binding member" of the claims presently on file, which render it difficult, if not impossible, to determine the matter for which protection (ligand, receptor or factor) is sought, the present application fails to comply with the clarity and conciseness requirements of Article 6 PCT (see also Rule 6.1(a) PCT) to such an extent that a meaningful search on the basis of the claims is impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear and concise, namely: Polypeptide variants of TNF according to the examples 1-10 and figures 1-4.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 2-3 and part of claim 1

Claims: 2-3 and part of claim 1 directed to TNFSF variants.

2. Claims: 4-9,14,26-28 and part of claim 1

Claims 4-9, 14, 26-28 and part of claim 1 directed to TNFRSF (SEQ ID No 76-79).

3. Claims: 10-13 an part of claim 1

Claims 10-13 and part of claim 1 directed to antibodies/MAb (SEQ ID No 13-30)

4. Claims: 15-16 and part of claim 1

Claims 15-16 and part of claim 1 directed to CTLD (SEQ ID No 104-105)

5. Claims: 17-21 and part of claim 1

Claims 17-21 and part of claim 1 directed to tetranectin variants (SEQ ID No 81, 106-109)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKewed/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.